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The	  most	  widely	  used	  method	  of	  creating	  tissue	  engineered	  vascular	  grafts	  (TEVGs)	  
for	  in	  vivo	  implantation	  consists	  of	  seeding	  autologous	  bone	  marrow	  cells	  (BMCs)	  
onto	  biodegradable	  scaffolds.	  In	  this	  model	  of	  TEVG	  development	  it	  has	  traditionally	  
been	  thought	  that	  stem	  cells	  and	  endothelial	  progenitor	  cells	  (EPCs)	  within	  the	  
seeded	  bone	  marrow	  population	  gave	  rise	  to	  the	  cells	  of	  the	  neovessel.	  	  Recent	  work	  
in	  our	  lab	  indicates	  that	  the	  seeded	  BMCs	  are	  not	  incorporated	  into	  the	  neovessel	  
and	  are	  actually	  rapidly	  lost	  from	  the	  implanted	  scaffold.	  	  Here	  we	  show	  the	  
feasibility	  of	  noninvasively	  monitoring	  this	  process	  by	  tracking	  ultrasmall	  
superparamagnetic	  iron	  oxide	  (USPIO)	  labeled	  macrophages	  with	  MRI.	  Murine	  
macrophages	  were	  labeled	  with	  USPIO	  through	  in	  vitro	  culture	  in	  media	  containing	  
2mg/ml	  of	  USPIO.	  The	  USPIO-­‐labeled	  macrophages	  were	  seeded	  onto	  polyglycolic	  
acid	  (PGA)	  scaffolds	  that	  were	  surgically	  implanted	  as	  inferior	  vena	  cava	  
interposition	  grafts	  in	  SCID/bg	  mice.	  	  Images	  were	  then	  obtained	  using	  a	  4.7T	  
Bruker	  horizontal	  bore	  scanner	  with	  an	  optimized	  RARE	  spin	  echo	  sequence	  and	  a	  
multislice-­‐multiecho	  sequence	  to	  determine	  the	  T2	  relaxation	  time	  with	  serial	  
imaging.	  The	  T2	  signal	  was	  found	  to	  be	  significantly	  lower	  immediately	  following	  
implantation	  of	  the	  USPIO	  labeled	  scaffolds	  (T2	  =	  44±6.8	  vs.	  71±10.2),	  but	  increased	  
rapidly	  to	  a	  value	  identical	  to	  that	  of	  control	  implants	  seeded	  with	  unlabeled	  
macrophages	  (T2	  =	  63±12	  vs.	  63±14).	  This	  strongly	  indicates	  the	  rapid	  loss	  of	  
seeded	  cells	  from	  the	  scaffolds,	  a	  finding	  verified	  using	  Prussian	  blue	  staining	  for	  
iron	  containing	  macrophages	  on	  histological	  sections	  of	  explanted	  TEVGs.	  Our	  
findings	  provide	  further	  support	  for	  the	  paradigm	  shift	  away	  from	  BMC	  neovessel	  
	  
incorporation	  towards	  the	  host	  cell	  based	  population	  of	  implanted	  TEVGs.	  
Furthermore,	  we	  	  demonstrate	  one	  of	  the	  first	  successful	  applications	  of	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Congenital	  heart	  defects	  (CHDs)	  occur	  in	  about	  1%	  of	  all	  live	  births,	  affecting	  
approximately	  40,000	  infants	  in	  the	  United	  States	  each	  year,	  and	  making	  CHDs	  the	  
most	  common	  congenital	  malformation	  in	  newborns	  (1,2).	  Although	  many	  of	  these	  
defects	  can	  be	  managed	  medically,	  there	  are	  still	  a	  number	  of	  complex	  CHDs	  that	  
rely	  on	  surgical	  correction	  to	  obtain	  an	  adequate	  circulation	  and	  to	  correct	  
structural	  defects	  that	  pose	  a	  threat	  to	  the	  normal	  development	  of	  the	  heart,	  lungs,	  
and	  other	  organs.	  	  It	  is	  estimated	  that	  each	  year	  approximately	  10,000	  children	  
undergo	  surgical	  reconstructive	  operations	  to	  repair	  complex	  congenital	  cardiac	  
abnormalities	  (3,4).	  While	  there	  have	  been	  significant	  advances	  in	  the	  field	  of	  
pediatric	  cardiothoracic	  surgery	  in	  the	  last	  20	  years	  that	  have	  resulted	  in	  well	  
documented	  reductions	  in	  surgical	  mortality	  and	  morbidity,	  there	  are	  still	  many	  
operations	  for	  the	  more	  complex	  CHDs	  that	  have	  shown	  limited	  long-­‐term	  outcome	  
improvements	  due	  to	  the	  limitations	  encountered	  with	  the	  use	  of	  currently	  available	  
prosthetic	  grafts	  (5).	  
Congenital	  heart	  defects	  consisting	  of	  single	  ventricle	  physiology	  are	  some	  of	  
the	  most	  severe	  forms	  of	  cyanotic	  heart	  disease,	  nearly	  universally	  requiring	  
surgical	  repair	  with	  a	  Fontan	  procedure	  (6).	  The	  most	  widely	  used	  surgical	  
technique	  consists	  of	  performing	  an	  extracardiac	  Fontan	  operation	  where	  the	  
venacaval	  circulation	  is	  shunted	  directly	  to	  the	  pulmonary	  circulation	  via	  an	  
extracardiac	  conduit	  (6-­‐9).	  While	  this	  technique	  has	  significantly	  improved	  the	  
morbidity	  and	  mortality	  associated	  with	  repair	  of	  this	  defect,	  it	  still	  has	  major	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drawbacks.	  The	  most	  widely	  cited	  disadvantage	  is	  the	  need	  to	  use	  prosthetic	  
conduits,	  which	  develop	  stenosis	  associated	  with	  the	  somatic	  growth	  of	  the	  child,	  
have	  inherent	  thrombogenic	  properties,	  and	  have	  a	  significant	  potential	  for	  
infection	  (6,10).	  	  Although	  the	  use	  of	  prosthetic	  grafts	  is	  life	  saving	  in	  many	  of	  these	  
situations,	  the	  substantial	  number	  of	  limitations	  associated	  with	  their	  use	  poses	  
special	  challenges	  for	  the	  pediatric	  population	  with	  predisposition	  of	  the	  surgical	  
recipient	  to	  repeat	  operations	  throughout	  their	  life	  (11).	  
The	  field	  of	  tissue	  engineering	  has	  provided	  an	  alternative	  solution	  aimed	  at	  
addressing	  many	  of	  these	  issues	  with	  the	  development	  of	  tissue	  engineered	  vascular	  
grafts	  (TEVGs).	  Tissue	  engineering	  is	  a	  type	  of	  regenerative	  medicine	  that	  utilizes	  
the	  principles	  of	  engineering	  along	  with	  the	  biological	  sciences	  to	  create	  neotissues	  
that	  are	  able	  to	  replace,	  repair,	  or	  regenerate	  damaged	  tissues	  (12,13).	  	  In	  vascular	  
tissue	  engineering,	  one	  of	  the	  main	  areas	  of	  focus	  has	  been	  the	  development	  of	  
autologous	  TEVGs	  that	  have	  the	  ability	  to	  grow	  and	  possess	  histological	  and	  
physiological	  functions	  similar	  to	  those	  of	  native	  tissue.	  	  These	  properties	  overcome	  
many	  of	  the	  limitations	  associated	  with	  the	  use	  of	  synthetic	  grafts	  and	  their	  use	  in	  
the	  pediatric	  population	  would	  represent	  a	  major	  advancement	  in	  the	  repair	  of	  
complex	  congenital	  heart	  defects.	  	  
Multiple	  studies	  have	  already	  demonstrated	  the	  ability	  to	  create	  tissue-­‐
engineered	  neovessels	  in	  vivo	  without	  any	  synthetic	  components	  that	  function	  like	  
native	  blood	  vessels	  (14-­‐16).	  	  	  These	  TEVGs	  are	  based	  on	  the	  classic	  tissue-­‐
engineering	  paradigm	  whereby	  autologous	  bone	  marrow	  mononuclear	  cells	  
(BMNCs)	  are	  harvested	  and	  seeded	  onto	  biodegradable	  scaffolds	  which	  serve	  as	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extracellular	  matrices,	  allowing	  for	  cellular	  adhesion	  and	  early	  structural	  integrity	  
(17).	  These	  structures	  are	  implanted	  in	  the	  host’s	  vasculature	  and,	  over	  a	  course	  of	  
six	  weeks,	  the	  scaffolds	  undergo	  degradation	  by	  hydrolysis,	  resulting	  in	  the	  
development	  of	  neovessels	  that	  have	  growth	  potential	  and	  resemble	  the	  native	  
vasculature	  in	  their	  biochemical,	  mechanical,	  and	  histological	  properties	  (18-­‐20).	  	  
The	  results	  from	  early	  animal	  models	  of	  TEVG	  development	  were	  so	  promising	  that	  
the	  first	  clinical	  application	  of	  this	  technology	  is	  already	  underway	  at	  Tokyo	  
Women’s	  Medical	  University	  in	  Japan	  (21,22).	  	  Between	  September	  2001	  and	  
December	  2004,	  25	  patients	  with	  single	  ventricle	  physiology	  underwent	  an	  
extracardiac	  total	  cavopulmonary	  connection	  (TCPC)	  using	  a	  tissue	  engineered	  
vascular	  graft.	  Late-­‐term	  follow	  up	  of	  this	  first-­‐in-­‐human	  clinical	  study	  has	  shown	  
promising	  results	  for	  the	  continued	  use	  of	  TEVGs	  to	  correct	  congenital	  heart	  defects	  
with	  single	  ventricle	  physiology	  (3,23).	  As	  of	  2009,	  the	  mean	  follow-­‐up	  was	  5.8	  
years	  and,	  up	  to	  this	  point,	  there	  had	  not	  been	  any	  graft-­‐related	  deaths.	  There	  were	  
six	  patients	  that	  demonstrated	  asymptomatic	  graft	  narrowing,	  of	  which	  four	  
underwent	  successful	  balloon	  angioplasty.	  In	  January	  of	  2009,	  the	  functional	  status	  
of	  all	  patients	  was	  assessed,	  showing	  that	  all	  surviving	  patients	  were	  attending	  
school	  or	  worked	  regularly,	  with	  17	  patients	  in	  New	  York	  Heart	  Association	  
functional	  class	  I,	  and	  3	  patients	  in	  functional	  class	  II.	  In	  anticipation	  of	  continued	  
clinical	  use	  and	  an	  upcoming	  clinical	  trial	  in	  the	  United	  States	  for	  which	  our	  group	  
has	  recently	  obtained	  FDA	  approval,	  the	  work	  in	  our	  lab	  has	  been	  focusing	  on	  
delineating	  the	  mechanisms	  of	  neovessel	  development	  with	  the	  goal	  of	  creating	  
improved,	  second	  generation	  TEVGs.	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In	  order	  to	  study	  the	  cellular	  and	  molecular	  mechanisms	  underlying	  TEVG	  
neovessel	  formation,	  our	  lab	  developed	  a	  murine	  model	  that	  allows	  for	  the	  
implantation	  and	  evaluation	  of	  human	  cells	  and	  tissues	  in	  SCID	  mice.	  This	  model	  has	  
been	  optimized	  for	  neovessel	  formation	  with	  both	  arterial	  and	  venous	  TEVGs	  
(19,24,25).	  	  Our	  lab	  has	  been	  using	  this	  model	  of	  TEVG	  development	  to	  better	  
understand	  the	  intricate	  process	  of	  neovessel	  development	  that	  occurs	  after	  
implantation	  of	  the	  seeded	  scaffold.	  Before	  the	  development	  of	  this	  model,	  it	  was	  
known	  that	  neovessels	  form	  after	  implantation	  of	  a	  biodegradable	  scaffolds	  seeded	  
with	  bone	  marrow	  mononuclear	  cells;	  however,	  the	  exact	  mechanisms	  and	  
requirements	  for	  successful	  development	  were	  poorly	  understood	  .	  Until	  recently,	  
the	  idea	  that	  stem	  cells	  and	  endothelial	  progenitor	  cells	  (EPCs)	  within	  the	  seeded	  
bone	  marrow	  population	  gave	  rise	  to	  the	  cells	  of	  the	  neovessel	  was	  the	  most	  widely	  
held	  belief	  about	  the	  mechanism	  of	  neovessel	  development	  (17,26).	  This	  theory	  was	  
based	  on	  evidence	  that	  vasculogenesis	  could	  take	  place	  beyond	  the	  embryonic	  
period	  through	  the	  migration	  and	  differentiation	  of	  circulating	  bone	  marrow	  
derived	  stem	  cells	  or	  endothelial	  progenitors	  at	  sites	  of	  ischemic	  injury	  and	  
vascularization	  (27).	  Various	  groups	  had	  reported	  evidence	  that	  bone	  marrow	  
derived	  endothelial	  progenitor	  cells	  circulate	  in	  the	  blood	  of	  adult	  organisms	  and	  
that	  mature	  endothelial	  cells	  can	  be	  derived	  by	  culturing	  and	  differentiating	  various	  
bone	  marrow	  populations	  (28-­‐30).	  Clinical	  investigations	  provided	  evidence	  that	  
mobilization	  of	  EPCs	  was	  increased	  in	  models	  of	  ischemia	  (29),	  as	  well	  as	  that	  the	  
transplantation	  of	  bone	  marrow	  progenitors	  led	  to	  increased	  blood	  flow	  in	  ischemic	  
injury	  (31,32).	  It	  was	  reported	  that	  the	  use	  of	  bone	  marrow	  cells	  in	  vascular	  tissue	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engineering	  increased	  endothelialization,	  and	  it	  was	  thought	  that	  the	  BMCs	  
differentiated	  into	  the	  endothelial	  and	  smooth	  muscle	  cells	  of	  tissue	  engineered	  
vascular	  grafts	  (17,26).	  	  
Several	  recently	  published	  studies	  from	  our	  lab	  have	  provided	  evidence	  
arguing	  against	  this	  school	  of	  thought.	  First	  of	  	  these	  came	  from	  tracking	  the	  fate	  of	  
seeded	  human	  bone	  marrow-­‐derived	  mononuclear	  cells	  (hBMCs)	  in	  our	  
immunodeficient	  mouse	  model	  of	  TEVG	  development	  through	  serial	  post-­‐
implantation	  monitoring	  with	  histology	  and	  PCR	  that	  showed	  a	  complete	  loss	  of	  
human	  cells	  within	  the	  TEVGs	  after	  one	  week	  (33).	  This	  evidence	  was	  further	  
supported	  by	  subsequent	  work	  in	  our	  laboratory	  tracking	  the	  fate	  of	  seeded	  
syngeneic	  bone	  marrow-­‐derived	  mononuclear	  cells	  labeled	  with	  GFP	  in	  an	  
immunocompetent	  mouse	  model,	  which	  similarly	  showed	  the	  rapid	  loss	  of	  cells	  by	  
GFP	  DNA	  quantification	  (unpublished	  data).	  In	  both	  instances,	  the	  loss	  of	  the	  seeded	  
BMCs	  was	  accompanied	  by	  a	  rapid	  infiltration	  of	  host	  monocytes/macrophages	  and,	  
eventually,	  by	  host	  endothelial	  and	  smooth	  muscle	  cells.	  This	  provides	  further	  
evidence	  that	  neovessel	  formation	  occurs	  through	  a	  process	  of	  inflammatory	  
vascular	  remodeling	  where	  the	  seeded	  BMCs	  act	  in	  a	  paracrine	  manner	  to	  recruit	  
host	  inflammatory	  cells	  (33).	  	  Similar	  findings	  by	  other	  groups	  also	  provide	  
evidence	  that	  BMCs	  are	  necessary	  for	  neovascularization	  by	  acting	  in	  a	  paracrine	  
manner	  and	  not	  by	  directly	  incorporating	  into	  the	  neovasculature	  (34,35).	  	  
While	  the	  evidence	  is	  plentiful	  to	  support	  this	  new	  hypothesis	  about	  the	  
origin	  of	  cells	  that	  give	  rise	  to	  neovessels,	  the	  methods	  that	  were	  used	  to	  perform	  
these	  experiments	  highlight	  one	  of	  the	  major	  limitations	  in	  the	  field	  of	  tissue	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engineering	  –	  the	  paucity	  of	  	  available	  tools	  for	  noninvasive	  cell	  tracking	  that	  allow	  
repeated	  observations	  of	  a	  single	  tissue-­‐engineered	  vessel	  as	  it	  undergoes	  dynamic	  
changes.	  	  To	  date,	  most	  in	  vivo	  experiments	  designed	  to	  study	  the	  mechanism	  of	  
neovessel	  development	  on	  the	  molecular	  and	  cellular	  level	  have	  required	  sacrificing	  
the	  animals	  at	  each	  observation	  point	  in	  order	  for	  the	  tissue	  to	  be	  harvested	  for	  
analysis,	  and	  thus	  precluding	  the	  ability	  to	  perform	  longitudinal	  observations	  in	  a	  
single	  animal	  (36).	  In	  this	  study,	  we	  use	  cellular	  MRI	  to	  track	  the	  fate	  of	  seeded	  cells	  
in	  a	  longitudinal	  model	  through	  serial	  imaging,	  providing	  first	  such	  evidence	  to	  our	  
knowledge	  by	  utilizing	  a	  noninvasive	  approach	  to	  study	  the	  mechanism	  of	  neovessel	  
development.	  As	  a	  result	  of	  rapid	  progress	  being	  made	  in	  several	  areas	  of	  tissue	  
engineering,	  noninvasive	  longitudinal	  monitoring	  is	  becoming	  increasingly	  more	  
important	  in	  clinical	  trials	  that	  require	  non-­‐invasive	  techniques	  for	  monitoring	  and	  
investigating	  cell	  therapies	  and	  neotissue	  development	  in	  host	  organisms.	  Such	  
noninvasive	  methods	  drastically	  decrease	  the	  number	  of	  required	  subjects	  and	  
associated	  costs,	  as	  well	  as	  open	  the	  door	  to	  human	  trials.	  Specifically,	  MRI	  is	  being	  
used	  to	  advance	  this	  research	  through	  noninvasive	  monitoring	  of	  tissue	  structures,	  
composition	  and	  function,	  in	  order	  to	  improve	  the	  tissue	  engineers’	  ability	  to	  direct	  
the	  process	  of	  neotissue	  development	  (37).	  	  
MRI	  has	  been	  the	  chosen	  imaging	  modality	  for	  accomplishing	  this	  because	  of	  
its	  ability	  to	  depict	  tissues	  with	  greater	  spatial	  resolution	  than	  other	  clinical	  imaging	  
modalities	  (38,39).	  MRI	  is	  further	  greatly	  enhanced	  with	  the	  use	  of	  targeted	  contrast	  
agents,	  giving	  it	  ability	  for	  near	  cellular	  resolution	  (40,41),	  as	  well	  as	  whole-­‐body	  
imaging	  capability	  without	  ionizing	  radiation	  (42-­‐47).	  MRI	  has	  the	  capability	  of	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imaging	  slices	  in	  any	  orientation,	  at	  any	  depth,	  with	  a	  resolution	  of	  approximately	  
100	  μm	  (37).	  Other	  imaging	  modalities	  such	  as	  optical	  and	  fluorescent	  microscopy	  
and	  micro-­‐CT	  have	  been	  used	  in	  tissue	  engineering,	  but	  each	  comes	  with	  limitations.	  
Intravital	  two-­‐photon	  fluorescence	  microscopy	  has	  been	  used	  to	  track	  fluorescently	  
labeled	  cells	  in	  tissue,	  but	  is	  not	  ideal	  for	  routine	  investigations	  in	  mice	  because	  of	  
its	  invasive	  nature	  and	  its	  ability	  to	  only	  image	  exposed	  or	  superficial	  explanted	  
tissue	  (48-­‐50).	  Micro-­‐CT	  has	  the	  ability	  to	  penetrate	  deeply	  into	  tissues,	  but	  uses	  
ionizing	  radiation	  and,	  in	  order	  to	  provide	  adequate	  contrast,	  requires	  dense	  tissue	  
(37).	  Similarly,	  single-­‐photon	  emission	  computed	  tomography	  and	  positron	  
emission	  tomography	  are	  able	  to	  penetrate	  deeply	  into	  tissue,	  but	  use	  radioactive	  
labels	  that	  can	  adversely	  affect	  living	  cells	  (51,52).	  	  MRI	  overcomes	  all	  of	  these	  
limitations,	  has	  the	  potential	  for	  imaging	  deep	  into	  tissue	  with	  high	  sensitivity	  and	  
spatiotemporal	  resolution	  with	  the	  ability	  to	  follow	  dynamic	  changes	  as	  the	  tissue-­‐
engineered	  constructs	  develop	  (53).	  In	  addition,	  no	  other	  imaging	  modality	  with	  
whole	  body	  imaging	  capability	  has	  shown	  single-­‐cell	  in	  vivo	  cell-­‐tracking	  ability	  
(40).	  	  
In	  order	  to	  perform	  in	  vivo	  cell	  tracking,	  targeted	  contrast	  agents	  are	  used	  to	  
label	  cells.	  To	  date,	  dextran	  coated	  superparamagnetic	  iron	  oxide	  (SPIO)	  
nanoparticles	  have	  been	  used	  as	  the	  leading	  contrast	  agents	  for	  cell	  tracking	  
purposes.	  The	  SPIO	  particles	  are	  distinguished	  based	  on	  their	  size	  after	  coating	  as	  
SPIO	  particles	  with	  a	  diameter	  of	  50-­‐150	  nm,	  ultrasmall	  superparamagnetic	  iron	  
oxide	  nanoparticles	  (USPIO)	  with	  a	  diameter	  less	  than	  50	  nm,	  and	  micron	  size	  
paramagnetic	  iron	  oxide	  particles	  (MPIO)(54).	  	  They	  are	  currently	  the	  most	  widely	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used	  contrast	  agents	  for	  cell	  tracking	  because	  MRI	  has	  greater	  sensitivity	  for	  
superparamagnetic	  agents	  over	  paramagnetic	  agents	  such	  as	  gadolinium-­‐	  based	  
agents	  which	  suffer	  from	  an	  inherently	  high	  threshold	  of	  detectability	  (55,42,47,56).	  	  
In	  addition,	  superparamagnetic	  agents	  are	  iron	  based	  and	  therefore	  benefit	  from	  a	  
low	  level	  of	  cellular	  toxicity.	  Multiple	  studies	  have	  shown	  that	  SPIO	  particles	  do	  not	  
adversely	  affect	  cell	  viability,	  physiology,	  differentiation,	  or	  migration	  ability	  
(54,57).	  	  These	  properties	  explain	  why	  it	  is	  currently	  the	  most	  widely	  used	  agent	  in	  
the	  fields	  of	  cellular	  and	  molecular	  MRI.	  	  
The	  fields	  of	  cellular	  and	  molecular	  MRI,	  which	  can	  be	  defined	  as	  the	  ”non-­‐
invasive	  and	  repetitive	  imaging	  of	  targeted	  cells	  or	  macromolecules	  in	  living	  
organisms,”	  (55)	  are	  two	  relatively	  new	  and	  rapidly	  growing	  fields	  that	  have	  the	  
potential	  to	  allow	  deeper	  insight	  into	  the	  underlying	  in	  vivo	  biology	  of	  many	  systems	  
and	  cellular	  processes	  without	  disturbing	  the	  native	  system	  dynamics.	  To	  date,	  most	  
uses	  of	  non-­‐invasive	  cellular	  imaging	  have	  been	  focused	  on	  macrophage	  imaging	  in	  
a	  wide	  range	  of	  applications	  including	  tumor	  staging,	  atherosclerotic	  change	  
visualization,	  and	  inflammatory	  CNS	  disease	  (58-­‐62).	  This	  predominantly	  arises	  
from	  the	  ease	  of	  labeling	  phagocytic	  cells	  with	  contrast	  agents,	  the	  preferential	  
phagocytosis	  of	  SPIO	  nanoparticles	  by	  monocytes	  and	  macrophages	  in	  vivo,	  and	  the	  
large	  cell	  numbers	  that	  accumulate	  at	  sites	  of	  inflammation	  that	  help	  overcome	  
detection	  limitations	  (54).	  In	  addition	  to	  macrophage	  imaging	  in	  vivo,	  several	  
research	  groups	  are	  beginning	  to	  use	  ex	  vivo	  labeling	  of	  various	  cell	  types	  with	  
subsequent	  injection	  and	  cell	  tracking	  in	  vivo,	  as	  well	  as	  SPIO	  nanoparticles	  that	  are	  
conjugated	  to	  target-­‐specific	  ligands	  (63,64).	  A	  few	  recent	  applications	  of	  cellular	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tracking	  utilizing	  MRI	  and	  SPIO-­‐labeled	  cells	  include	  visualizing	  neural	  stem	  cell	  
migration	  to	  cortical	  inflammatory	  lesions,	  monitoring	  transplanted	  pancreatic	  
islets,	  and	  monitoring	  mesenchymal	  stem	  cells	  transplanted	  into	  infarcted	  
myocardium	  (65-­‐67).	  	  
The	  available	  studies	  are	  even	  more	  limited	  with	  respect	  to	  molecular	  MRI	  
(mMRI).	  Molecular	  MRI	  uses	  MRI	  contrast	  agents	  as	  probes	  by	  linking	  them	  to	  
specific	  monoclonal	  antibodies	  that	  are	  targeted	  to	  specific	  receptors	  or	  antigens.	  
The	  most	  recently	  published	  work	  in	  this	  field	  is	  by	  Towner	  et	  al.	  (68)	  and	  involves	  
using	  magnetite-­‐based	  dextran-­‐coated	  nanoparticles	  covalently	  bound	  to	  VEGF-­‐R2	  
antibodies	  that	  serve	  as	  mMRI	  probes	  to	  detect	  in	  vivo	  levels	  of	  VEGF-­‐R2	  as	  a	  
marker	  of	  angiogenesis	  in	  gliomas.	  	  MR	  images	  of	  glioma-­‐bearing	  rat	  brains	  
appeared	  hypodense	  at	  the	  location	  of	  gliomas	  in	  animals	  injected	  with	  the	  iron-­‐
oxide	  nanoparticle	  probes,	  compared	  to	  control	  mice	  injected	  with	  regular	  
antibodies.	  The	  authors	  concluded	  that	  this	  showed	  the	  feasibility	  of	  using	  mMRI	  to	  
assess	  angiogenesis	  in	  an	  in	  vivo	  model	  and	  that	  this	  could	  easily	  be	  extended	  to	  the	  
field	  of	  vascular	  tissue	  engineering.	  	  
Similarly	  to	  most	  of	  the	  research	  in	  other	  fields,	  the	  most	  widely	  used	  
contrast	  agents	  for	  cellular	  MRI	  in	  tissue	  engineering	  applications	  are	  based	  on	  
labeling	  cells	  with	  superparamagnetic	  iron	  oxide	  nanoparticles.	  	  During	  the	  last	  five	  
years	  most	  applications	  have	  predominantly	  consisted	  of	  enhancing	  seeding	  
techniques	  and	  visualization	  of	  cell	  seeding	  efficiency	  and	  distribution	  both	  in	  vitro	  
and	  in	  vivo	  (69-­‐72).	  Perea	  et	  al.	  (69)	  labeled	  human	  umbilical	  vein	  endothelial	  cells	  
(HUVECs)	  with	  SPIO	  nanoparticles	  and	  then	  used	  an	  electromagnet	  to	  direct	  cell	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seeding	  onto	  the	  lumen	  of	  a	  polytetrafluoroethylene	  (PTFE)	  tubular	  graft	  with	  
subsequent	  visualization	  by	  MRI	  to	  analyze	  cellular	  distribution.	  Shimizu	  et	  al.	  (70)	  
described	  another	  technique	  referred	  to	  as	  Mag-­‐seeding	  in	  which	  NIH/3T3	  
fibroblasts	  (3T3s)	  were	  labeled	  with	  magnetite	  cationic	  liposomes	  (MCLs)	  and	  then	  
seeded	  onto	  a	  decellularized	  porcine	  common	  carotid	  artery	  by	  inserting	  a	  
cylindrical	  magnet	  into	  the	  lumen	  of	  the	  artery	  and	  then	  submersing	  the	  unit	  into	  a	  
suspension	  of	  labeled	  3T3s.	  Wilhelm	  et	  al.	  (73)	  was	  able	  to	  show	  that	  the	  formation	  
of	  vascular	  networks	  could	  be	  directed	  in	  Matrigel	  models	  of	  in	  vitro	  vascularization	  
by	  using	  a	  magnetic	  field	  to	  move	  magnetically	  labeled	  endothelial	  progenitor	  cells.	  
Most	  recently,	  published	  data	  by	  Poirier-­‐Quinot	  et	  al.	  (74)	  demonstrated	  the	  
potential	  of	  using	  a	  high	  resolution	  1.5-­‐T	  MRI	  for	  noninvasive	  3D	  visualization	  of	  
tissue	  engineered	  scaffolds	  seeded	  with	  iron	  oxide	  labeled	  mesenchymal	  stem	  cells	  
(MSCs)	  both	  before	  and	  after	  implantation	  subcutaneously	  in	  mice.	  They	  proved	  the	  
feasibility	  of	  using	  high-­‐resolution	  1.5-­‐T	  MRI	  to	  visualize	  the	  architecture	  of	  their	  
scaffolds	  and	  to	  study	  and	  characterize	  3-­‐dimensional	  cell	  seeding	  both	  in	  vitro	  and	  
after	  subcutaneous	  scaffold	  implantation.	  This	  represents	  a	  proof-­‐of-­‐principle	  study	  
that	  shows	  the	  feasibility	  of	  using	  this	  technique	  to	  follow	  longitudinal	  cell	  
migration	  from	  the	  time	  of	  scaffold	  implantation	  both	  throughout	  the	  scaffold	  itself	  
and	  from	  the	  scaffold	  to	  other	  areas	  of	  the	  body.	  This	  is	  the	  direction	  the	  field	  of	  
cellular	  MRI	  is	  progressing	  in	  tissue	  engineering	  applications.	  	  
Recently,	  there	  have	  been	  more	  studies	  in	  the	  literature	  that	  have	  advanced	  
beyond	  using	  iron	  oxide	  nanoparticles	  to	  simply	  enhance	  cell	  seeding	  techniques	  to	  
explore	  the	  usefulness	  of	  cellular	  MRI	  for	  tracking	  the	  fate	  of	  cells	  seeded	  onto	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scaffolds	  intended	  for	  tissue	  regeneration.	  While	  most	  of	  these	  studies	  are	  based	  on	  
in	  vitro	  work,	  there	  have	  been	  several	  investigations	  that	  have	  utilized	  in	  vivo	  
approaches	  to	  demonstrate	  the	  feasibility	  of	  using	  this	  technology	  to	  advance	  our	  
understanding	  of	  the	  dynamic	  changes	  occurring	  post-­‐implantation.	  Terrovitis	  et	  al.	  
(75)	  was	  one	  of	  the	  first	  groups	  to	  look	  at	  the	  possibility	  of	  using	  cellular	  MRI	  to	  
visualize	  SPIO-­‐labeled	  human	  mesenchymal	  stem	  cells	  (MSCs)	  seeded	  onto	  1%	  type	  
I	  bovine	  collagen	  scaffolds	  intended	  for	  use	  as	  tissue-­‐engineered	  heart	  valves.	  They	  
labeled	  MSCs	  with	  ferumoxide	  nanoparticles,	  demonstrated	  that	  the	  cell	  labeling	  did	  
not	  cause	  adverse	  effects	  on	  the	  cells,	  and	  then	  showed	  by	  in	  vitro	  T2	  weighted	  MRI	  
that	  the	  labeled	  cells	  seeded	  onto	  the	  scaffolds	  could	  be	  visualized	  as	  areas	  of	  
reduced	  signal	  intensity	  with	  a	  40-­‐50%	  shorter	  T2	  relaxation	  time	  than	  similar	  
unlabeled	  cells.	  This	  was	  one	  of	  the	  first	  studies	  to	  show	  the	  promise	  of	  using	  these	  
techniques	  for	  cell	  tracking	  in	  future	  tissue-­‐engineering	  applications.	  	  
Heymer	  et	  al.	  (76)	  performed	  a	  similar	  study	  looking	  at	  the	  feasibility	  of	  
using	  very	  small	  superparamagnetic	  iron	  oxide	  particles	  (VSOPs)	  to	  label	  MSCs	  for	  
the	  purpose	  of	  creating	  a	  reliable	  cell	  monitoring	  technique	  in	  articular	  cartilage	  
repair.	  They	  labeled	  MSCs	  with	  the	  VSOPs,	  demonstrated	  that	  cell	  viability	  was	  not	  
affected,	  and	  then	  performed	  high-­‐resolution	  MRI	  of	  the	  VSOP-­‐labeled	  MSCs	  
embedded	  in	  a	  clinically	  used	  collagen	  type	  I	  hydrogel.	  Similarly	  to	  Terrovitis	  et	  al.,	  
this	  study	  was	  performed	  entirely	  in	  vitro	  and	  demonstrated	  the	  potential	  for	  using	  
MRI	  to	  track	  the	  migration	  of	  the	  VSOP-­‐labeled	  cells	  post-­‐implantation.	  	  
The	  first	  in	  vivo	  applications	  of	  these	  methods	  have	  been	  published	  recently	  
and	  consist	  mostly	  of	  demonstrating	  the	  ability	  to	  visualize	  the	  labeled	  cells	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immediately	  after	  scaffold	  implantation.	  Saldanha	  et	  al.	  (77)	  demonstrated	  the	  
ability	  to	  visualize	  ferumoxide-­‐labeled	  MSCs	  in	  an	  ex	  vivo	  rat	  model	  of	  a	  tissue	  
engineering	  based	  approach	  to	  the	  regeneration	  of	  the	  intervertebral	  disc.	  
Ferumoxide-­‐labeled	  MSCs	  were	  loaded	  into	  polyethylene	  glycol	  hydrogels	  and	  
imaged	  in	  vitro,	  verifying	  the	  ability	  to	  detect	  the	  labeled	  cells	  on	  T2-­‐weighted	  MRI	  
through	  signal	  intensity	  loss.	  Next,	  labeled	  cells	  were	  loaded	  into	  fibrin	  gels	  and	  
injected	  into	  the	  intervertebral	  disc	  spaces	  of	  excised	  rat	  tails	  and	  imaged.	  It	  was	  
shown	  that	  discs	  injected	  with	  the	  ferumoxide	  labeled	  cells	  appeared	  darker	  on	  T2	  
weighted	  images	  than	  discs	  injected	  with	  fibrin	  gel	  alone.	  The	  authors	  concluded	  
that	  this	  provided	  the	  potential	  for	  in	  vivo	  longitudinal	  tracking	  of	  MSCs	  in	  the	  tissue	  
engineering	  based	  approach	  to	  intervertebral	  disc	  regeneration.	  Ko	  et	  al.	  (78)	  went	  
one	  step	  further	  by	  monitoring	  gelatin	  sponges	  seeded	  with	  SPIO-­‐labeled	  MSCs	  that	  
were	  implanted	  subcutaneously	  in	  the	  hind	  limbs	  of	  nude	  mice.	  	  Serial	  MRIs	  were	  
performed	  over	  a	  period	  of	  4	  weeks	  demonstrating	  the	  ability	  to	  visualize	  the	  
gelatin	  sponge	  containing	  the	  SPIO-­‐labeled	  MSCs	  as	  a	  hypodense	  region	  in	  the	  hind	  
limbs	  of	  the	  animals.	  They	  concluded	  that	  the	  area	  of	  hypodensity	  increased	  over	  
the	  4-­‐week	  period	  as	  the	  seeded	  MSCs	  spread	  out	  from	  the	  implanted	  gelatin	  
sponges.	  This	  represents	  one	  of	  the	  first	  published	  works	  verifying	  the	  ability	  to	  use	  
cellular	  MRI	  to	  track	  seeded	  cells	  in	  an	  in	  vivo	  tissue	  engineering	  model.	  Although	  
this	  study	  was	  using	  a	  quasi-­‐tissue	  engineering	  product	  and	  was	  not	  focused	  on	  a	  
specific	  tissue	  engineering	  application,	  it	  still	  laid	  the	  foundation	  for	  using	  SPIO	  cell	  
labeling	  and	  cellular	  MRI	  for	  in	  vivo	  longitudinal	  cell	  tracking	  in	  tissue	  engineering	  
applications.	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One	  of	  the	  first	  studies	  that	  applied	  SPIO	  cell	  labeling	  and	  MR	  cell	  tracking	  to	  
a	  specific	  tissue	  engineering	  application	  was	  performed	  in	  our	  laboratory	  by	  Nelson	  
et	  al.	  (79)	  in	  the	  field	  of	  vascular	  tissue	  engineering.	  Nelson	  et	  al.	  conducted	  a	  pilot	  
study	  using	  human	  aortic	  smooth	  muscle	  cells	  (hASMCs)	  labeled	  with	  ultrasmall	  
superparamagnetic	  iron	  oxide	  nanoparticles	  (USPIOs)	  that	  were	  seeded	  onto	  tissue	  
engineered	  vascular	  grafts	  (TEVGs)	  and	  implanted	  as	  aortic	  interposition	  grafts	  in	  
C.B.-­‐17	  SCID/bg	  mice.	  Mice	  were	  then	  imaged	  at	  different	  time	  points	  over	  a	  3-­‐week	  
period	  demonstrating	  that	  the	  TEVGs	  seeded	  with	  USPIO-­‐labeled	  cells	  appeared	  
darker	  on	  T2	  weighted	  images	  than	  unseeded	  scaffolds.	  It	  was	  concluded	  that	  USPIO	  
cell	  labeling	  enhanced	  visualization	  of	  the	  tissue	  engineered	  vascular	  constructs	  in	  
vivo,	  demonstrating	  the	  feasibility	  of	  applying	  noninvasive	  MR	  cell	  tracking	  
techniques	  for	  evaluation	  of	  in	  vivo	  TEVG	  performance.	  	  
There	  have	  not	  been	  any	  studies	  in	  the	  field	  of	  vascular	  tissue	  engineering	  
that	  have	  utilized	  cellular	  MRI	  to	  answer	  questions	  regarding	  the	  process	  of	  
neotissue	  development	  once	  the	  tissue	  engineered	  constructs	  are	  implanted.	  A	  
study	  of	  this	  nature	  would	  require	  serial	  imaging	  of	  labeled	  cells	  in	  a	  live	  animal	  
model	  of	  vascular	  tissue	  engineering.	  The	  studies	  previously	  mentioned	  have	  set	  the	  
background	  for	  utilizing	  this	  technology	  to	  answer	  such	  questions	  from	  a	  
noninvasive	  standpoint,	  instead	  of	  current	  methods	  that	  require	  the	  tissue	  
engineered	  constructs	  to	  be	  excised,	  usually	  terminating	  the	  animals	  for	  analysis.	  
Given	  our	  interest	  in	  clinical	  applications	  of	  TEVGs	  in	  congenital	  cardiac	  defect	  
repairs,	  which	  typically	  occur	  in	  the	  low	  pressure	  venous	  system,	  in	  this	  study	  we	  
sought	  to	  demonstrate	  our	  ability	  to	  serially	  track	  USPIO-­‐labeled	  macrophages	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seeded	  onto	  our	  TEVGs	  after	  they	  are	  implanted	  as	  interposition	  grafts	  in	  the	  
inferior	  vena	  cavas	  of	  SCID/bg	  mice	  for	  the	  purpose	  of	  determining	  the	  fate	  of	  
seeded	  cells	  and	  their	  role	  in	  venous	  neovessel	  formation.	  	  	  
In	  order	  to	  achieve	  this,	  murine	  macrophages	  were	  labeled	  with	  USPIO	  
through	  in	  vitro	  culture	  in	  media	  containing	  USPIO.	  The	  USPIO-­‐labeled	  macrophages	  
were	  seeded	  onto	  polyglycolic	  acid	  (PGA)	  scaffolds	  that	  were	  surgically	  implanted	  
as	  inferior	  vena	  cava	  interposition	  grafts	  in	  SCID/bg	  mice.	  	  Images	  were	  then	  
obtained	  on	  a	  4.7T	  Bruker	  horizontal	  bore	  scanner	  with	  an	  optimized	  RARE	  spin	  
echo	  sequence	  and	  a	  multislice-­‐multiecho	  sequence	  to	  determine	  T2	  relaxation	  time	  
with	  serial	  imaging.	  The	  signal	  intensities	  were	  verified	  using	  Prussian	  blue	  staining	  
for	  iron	  containing	  macrophages.	  To	  our	  knowledge,	  this	  is	  the	  first	  study	  
performed	  in	  vascular	  tissue	  engineering	  that	  utilizes	  serial	  MR	  imaging	  of	  a	  TEVG	  












Statement	  of	  Purpose	  
The	  overall	  aim	  of	  this	  project	  is	  to	  utilize	  cellular	  MR	  imaging	  to	  
noninvasively	  track	  the	  fate	  of	  cells	  seeded	  onto	  tissue	  engineered	  vascular	  grafts	  
(TEVGs)	  after	  in	  vivo	  implantation.	  	  We	  hypothesize	  that	  the	  seeded	  cells	  will	  be	  
rapidly	  lost	  from	  the	  implanted	  scaffold	  and	  that	  this	  loss	  will	  be	  detected	  by	  an	  
increase	  in	  T2	  signal.	  In	  order	  to	  accomplish	  this,	  we	  will	  optimize	  the	  conditions	  for	  
labeling	  macrophage	  populations	  with	  USPIO	  nanoparticles.	  After	  labeling	  
conditions	  have	  been	  determined	  not	  to	  affect	  cell	  viability,	  we	  will	  determine	  the	  
limit	  of	  detection	  of	  the	  labeled	  cells	  and	  verify	  the	  ability	  to	  visualize	  the	  labeled	  
cells	  on	  TEVGs	  in	  vitro.	  Finally	  we	  will	  implant	  USPIO-­‐labeled	  scaffolds	  as	  Infrarenal	  
IVC	  interposition	  grafts	  in	  SCID/bg	  mice	  and	  perform	  serial	  MR	  imaging	  and	  T2	  













Materials	  and	  Methods	  
Biodegradable	  Scaffolds	  	  
Scaffolds	  were	  constructed	  from	  a	  nonwoven	  polyglycolic	  acid	  (PGA)	  mesh	  felt	  
(ConcordiaFibers,	  Coventry,	  RI,	  USA)	  and	  coated	  with	  a	  50:50	  co-­‐polymer	  sealant	  
solution	  of	  poly-­‐L-­‐lactide	  and	  ε-­‐caprolactone	  (P(CL/LA)).	  The	  PGA	  mesh	  felts	  were	  
shaped	  into	  tubes	  by	  introducing	  6.0	  x	  6.0	  mm	  sections	  into	  the	  inlet	  of	  a	  cylinder	  
with	  an	  internal	  diameter	  of	  1.4mm.	  Stainless	  steel	  21-­‐gauge	  needles	  were	  then	  
introduced	  into	  the	  opposing	  end	  to	  maintain	  the	  inner	  lumen	  and	  compress	  the	  felt.	  
A	  5%	  (w/v)	  P(CL/LA)	  (263.8	  kDa;	  Absorbable	  Polymers	  International,	  Birmingham,	  
AL,	  USA)	  in	  dioxane	  sealant	  solution	  was	  injected	  into	  the	  inlet	  of	  the	  chamber	  
system	  and	  allowed	  to	  penetrate	  the	  felt.	  The	  scaffolds	  were	  then	  frozen	  at	  –20°C	  for	  
20	  min	  and	  lyophilized	  for	  24	  hours.	  This	  resulted	  in	  PGA-­‐P(CL/LA)	  scaffolds	  with	  
an	  internal	  diameter	  of	  0.9	  mm.	  
(Scaffolds	  were	  made	  by	  Jamie	  K.	  Harrington)	  
Cell	  Culture	  
Murine	  macrophages	  (Cell	  Line	  Raw	  264.7	  (ATCC®)	  were	  cultured	  in	  RPMI	  Media	  
1640	  containing	  10%	  (vol/vol)	  FBS	  and	  1%	  (vol/vol)	  Penicillin/Streptomycin	  
(GIBCO®).	  Cells	  were	  harvested	  between	  passages	  3	  and	  6	  for	  all	  experiments.	  	  
(Performed	  by	  Jamie	  K.	  Harrington)	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Incubation	  of	  Murine	  Macrophages	  with	  USPIO	  Nanoparticles	  
Commercially	  available	  USPIO	  nanoparticles	  (Molday	  ION	  (-­‐)	  Biophysics	  Assay	  
Laboratory,	  Inc,	  Worcester,	  MA)	  were	  supplied	  in	  2	  ml	  sterile	  sealed	  serum	  bottles	  
with	  a	  concentration	  of	  10	  mg	  Fe/ml.	  This	  stock	  solution	  of	  USPIO	  nanoparticles	  
was	  diluted	  directly	  into	  murine	  macrophage	  serum	  free	  culture	  media	  (SFM)	  
(RPMI-­‐1640	  with	  1%	  (vol/vol)	  Penicillin/Streptomycin,	  GIBCO®)	  for	  all	  
experiments.	  	  Murine	  macrophages	  were	  incubated	  at	  an	  optimized	  USPIO	  
concentration	  of	  2	  mg/ml	  for	  36	  hours	  in	  SFM.	  	  
(Performed	  by	  Jamie	  K.	  Harrington)	  
Coating	  USPIO	  Nanoparticles	  with	  Poly-­l-­lysine	  
In	  some	  experiments,	  the	  USPIO	  nanoparticles	  were	  pre-­‐incubated	  with	  a	  solution	  
of	  high	  molecular	  weight	  poly-­‐L-­‐lysine	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO,	  USA)	  in	  order	  
to	  enhance	  uptake.	  30	  mg	  of	  Combidex	  nanoparticles	  were	  added	  to	  15	  ml	  of	  serum-­‐
free	  high-­‐glucose	  Dulbecco’s	  modified	  Eagle	  medium	  (DMEM;	  Invitrogen,	  Carlsbad,	  
CA,	  USA).	  This	  solution	  was	  mixed	  with	  1.8	  mg	  of	  poly-­‐l-­‐lysine	  dissolved	  in	  15	  ml	  of	  
high-­‐glucose	  DMEM	  for	  1	  h	  on	  an	  orbital	  shaker,	  which	  produced	  30	  ml	  of	  stock	  
solution	  containing	  USPIO	  and	  poly-­‐l-­‐lysine	  concentrations	  of	  1000	  μg/ml	  and	  60	  
μg/ml,	  respectively.	  This	  ratio	  of	  USPIO	  to	  poly-­‐l-­‐lysine	  was	  held	  constant	  
throughout	  all	  serial	  dilution	  studies.	  
(Performed	  by	  Jamie	  K.	  Harrington)	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Prussian	  Blue	  Staining	  and	  Labeling	  Efficiency	  Determination	  
Prussian	  Blue	  staining	  for	  intracellular	  iron	  was	  performed	  on	  macrophages	  
incubated	  with	  USPIO	  nanoparticles	  to	  determine	  the	  labeling	  efficiency.	  
Macrophages	  were	  incubated	  for	  36	  hours	  with	  a	  2	  mg/ml	  concentration	  of	  USPIO	  
nanoparticles.	  Following	  the	  incubation	  period,	  the	  cells	  were	  washed	  3	  times	  with	  
PBS,	  trypsinized,	  and	  plated	  onto	  sterile	  microscope	  coverslips.	  Once	  adherent,	  the	  
cells	  were	  fixed	  in	  10%	  neutral	  buffered	  formalin	  (NBF;	  Sigma-­‐Aldrich)	  overnight	  
and	  stained	  for	  the	  presence	  of	  intracellular	  iron.	  Potassium	  ferrocyanate	  (4%	  w/v	  
in	  distilled	  water)	  was	  mixed	  with	  a	  20%	  w/v	  solution	  of	  hydrochloric	  acid	  right	  
before	  use.	  The	  cells	  were	  then	  exposed	  to	  this	  mixture	  for	  20	  minutes	  before	  being	  
washed	  3	  times	  with	  distilled	  water.	  Cells	  were	  then	  counterstained	  with	  nuclear	  
fast	  red	  counterstain	  (Sigma-­‐Aldrich)	  at	  room	  temperature	  for	  5	  minutes.	  Labeling	  
efficiencies	  were	  determined	  by	  counting	  the	  fraction	  of	  cells	  staining	  positive	  for	  
Prussian	  blue.	  Macrophages	  receiving	  no	  USPIO	  served	  as	  controls	  negative	  controls	  
and	  spleen	  tissue	  sections	  served	  as	  positive	  controls.	  	  	  
(Performed	  by	  Jamie	  K.	  Harrington)	  
Cell	  Metabolism	  Assay	  
In	  order	  to	  determine	  macrophage	  metabolic	  activity	  following	  USPIO	  labeling,	  a	  
CellTiter	  96®	  AQueous	  Non-­‐Radioactive	  Cell	  Proliferation	  Assay	  (MTS)	  (Promega	  
Corporation,	  Madison,	  WI,	  USA)	  was	  performed.	  Macrophags	  were	  incubated	  for	  36	  
hours	  with	  2	  mg/ml	  of	  USPIO	  nanoparticles.	  Following	  the	  incubation	  period,	  the	  
cells	  were	  washed	  3	  times	  with	  PBS	  and	  the	  assay	  reagent	  (tetrazolium	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compound(3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐5-­‐(3-­‐carboxymethoxyphenyl)-­‐2-­‐(4-­‐
sulfophenyl)-­‐2H-­‐tetrazolium,	  inner	  salt;	  MTS)	  and	  an	  electron	  coupling	  reagent	  
(phenazine	  methosulfate;	  PMS))	  was	  added	  to	  the	  cells	  at	  an	  1:4	  ratio	  with	  media	  
and	  allowed	  to	  incubate	  for	  4	  hours	  at	  37C.	  After	  4	  hours,	  a	  100	  μl	  aliquot	  of	  each	  
sample	  was	  added	  to	  a	  clear	  96-­‐well	  plate	  and	  the	  absorbance	  at	  490	  nm	  was	  read.	  
The	  relative	  cell	  metabolic	  activity	  was	  determined	  as	  the	  ratio	  of	  absorbance	  from	  
wells	  incubated	  with	  USPIO	  to	  the	  control	  wells	  (receiving	  no	  USPIO).	  Experiments	  
were	  performed	  in	  triplicate.	  	  
(Performed	  by	  Jamie	  K.	  Harrington)	  
Flow	  Cytometry	  
In	  order	  to	  determine	  macrophage	  cell	  viability	  after	  USPIO	  labeling,	  7-­‐
aminoactinomycin	  D	  (7-­‐AAD)	  Flow	  Cytometry	  was	  performed	  and	  compared	  to	  
macrophages	  receiving	  no	  USPIO	  concentration.	  For	  flow	  cytometry,	  cells	  were	  
pipetted	  up	  and	  down	  several	  times	  to	  remove	  attached	  cells	  and	  to	  break	  up	  
clumps.	  	  Cells	  were	  then	  passed	  through	  a	  100	  μm	  cell	  strainer	  and	  transferred	  to	  5	  
ml	  polypropylene	  tubes	  (BD	  Bioscience,	  San	  Jose	  CA).	  After	  centrifugation	  to	  pellet	  
cells	  (200	  x	  g	  for	  10	  minutes),	  cells	  were	  resuspended	  in	  100	  μl	  staining	  buffer	  (PBS	  
with	  1%	  fetal	  bovine	  serum	  and	  0.1%	  sodium	  azide).	  	  To	  assess	  viability,	  20	  μl	  of	  
Viaprobe	  (BD	  Bioscience)	  was	  added	  to	  each	  tube	  and	  incubated	  on	  ice	  for	  10	  
minutes.	  	  Next,	  200	  μl	  of	  staining	  buffer	  was	  added	  and	  the	  cells	  were	  analyzed	  on	  a	  
FACSAria	  cell	  sorter	  (BD	  Bioscience).	  Results	  were	  analyzed	  using	  Flowjo	  (Tree	  Star	  
Inc.	  Ashland,	  OR).	  Experiments	  were	  performed	  in	  triplicate.	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(Performed	  by	  Lesley	  Devine	  in	  Laboratory	  Medicine)	  
Macrophage	  Seeding	  of	  Polymer	  Scaffolds	  	  
Each	  PGA-­‐P(CL/LA)	  scaffold	  was	  trimmed	  to	  4	  mm	  in	  length	  and	  sterilized	  via	  
incubation	  at	  20°C	  under	  UV	  light	  in	  sterile	  PBS.	  Scaffolds	  were	  washed	  in	  sterile	  
PBS	  prior	  to	  seeding.	  Macrophages	  were	  trypsinized	  and	  collected	  for	  seeding	  in	  
RPMI-­‐1640	  media.	  Approximately	  5x106	  cells	  were	  statically	  seeded	  onto	  each	  
scaffold	  by	  directly	  pipetting	  the	  cell	  suspension	  into	  the	  lumen	  through	  both	  ends.	  
The	  scaffold	  was	  then	  gently	  compressed	  to	  encourage	  cell	  infiltration	  into	  the	  
porous	  walls.	  This	  process	  of	  pipetting	  and	  compression	  was	  repeated	  3	  times	  at	  
each	  end	  of	  the	  scaffold.	  Each	  seeded	  scaffold	  was	  then	  allowed	  to	  sit	  for	  15	  min	  to	  
allow	  cell	  adhesion.	  A	  21-­‐gauge	  needle	  was	  then	  gently	  threaded	  through	  the	  lumen	  
of	  the	  graft	  to	  prevent	  occlusion	  via	  cellular	  ingrowth	  and	  each	  graft	  was	  incubated	  
overnight	  in	  3	  ml	  of	  RPMI-­‐1640	  media.	  	  
(Performed	  by	  Jamie	  K.	  Harrington)	  
Seeding	  Efficiency	  Determination	  	  
Prior	  to	  in	  vivo	  application,	  it	  was	  important	  to	  determine	  if	  the	  seeding	  efficiency	  of	  
the	  USPIO	  labeled	  macrophages	  on	  the	  scaffolds	  was	  sufficient	  to	  be	  detected	  by	  
MRI.	  Various	  numbers	  of	  USPIO-­‐labeled	  macrophages	  (1x106,	  5x106,	  10x106,	  and	  
15x106)	  were	  statically	  seeded	  onto	  biodegradable	  PGA-­‐P(CL/LA)	  scaffold	  
constructs	  as	  previously	  described.	  Seeding	  efficiency	  was	  then	  determined	  by	  
measuring	  the	  DNA	  content	  on	  the	  scaffolds	  with	  the	  PicoGreen	  detection	  assay	  
(Quant-­‐iTTM	  PicoGreen®	  dsDNA	  Assay	  Kit,	  Molecular	  Probes	  Inc,	  Eugene,	  OR)	  
26	  
following	  a	  24	  hour	  incubation.	  After	  the	  24	  hour	  in	  vitro	  incubation,	  the	  seeded	  
scaffolds	  were	  rinsed	  3	  times	  in	  PBS,	  placed	  in	  200	  μL	  of	  distilled	  water,	  and	  stored	  
at	  	  -­‐80°C	  for	  a	  minimum	  of	  24	  hours.	  At	  the	  time	  of	  evaluation,	  scaffold	  sections	  
were	  thawed	  at	  37.8°C.	  A	  black	  96-­‐well	  plate	  was	  loaded	  with	  50	  μL	  from	  each	  
sample.	  A	  30	  μl	  aliquot	  of	  the	  PicoGreen	  dye	  was	  mixed	  thoroughly	  with	  6	  ml	  of	  
Tris-­‐EDTA	  buffer	  (pH	  7.5)	  and	  50	  μl	  was	  added	  to	  each	  sample	  in	  the	  96-­‐well	  plate.	  
All	  samples	  were	  performed	  in	  triplicate.	  The	  plate	  was	  incubated	  in	  the	  dark	  at	  
room	  temperature	  for	  10	  minutes.	  Fluorescence	  was	  measured	  at	  488	  nm	  excitation	  
and	  525	  nm	  emission.	  The	  number	  of	  cells	  maintained	  on	  each	  scaffold	  was	  
determined	  from	  a	  standard	  curve	  generated	  from	  a	  known	  quantity	  of	  
macrophages.	  A	  negative	  control	  of	  unseeded	  scaffold	  sections	  was	  used	  for	  
comparison.	  	  
(Performed	  by	  Jamie	  K.	  Harrington)	  
MRI 
All	  MRI	  experiments	  were	  performed	  on	  a	  4.7T	  Bruker	  horizontal-­‐bore	  system	  with	  
custom-­‐made	  bird	  cage	  coils.	  
(All	  MRI	  samples	  were	  prepared	  for	  MRI	  by	  Jamie	  K.	  Harrington;	  The	  MRI	  sequences	  
were	  run	  by	  Halima	  Chahboune	  in	  the	  Biomedical	  Engineering	  Department;	  The	  
scaffold	  implants	  were	  performed	  by	  Naru	  Hibino	  and	  Tai	  Yi	  in	  the	  
Interdepartmental	  Program	  in	  Vascular	  Biology	  and	  Therapeutics;	  Anesthesia	  was	  




In	  vitro	  MRI	  
To	  determine	  the	  minimal	  quantity	  of	  detectable	  cells,	  decreasing	  numbers	  of	  
labeled	  cells	  (25x106,	  20x106,	  15x106,	  10x106,	  5x106,	  and	  1x106),	  and	  unlabeled	  
cells	  were	  imaged.	  For	  T2-­‐weighted	  images	  a	  spin-­‐echo	  (SE)	  sequence	  was	  used	  
with	  the	  following	  parameters:	  TR/TE	  =	  3000/20	  ms;	  matrix	  size=	  128×128;	  FOV	  =	  
32×32	  mm;	  slice	  thickness	  =	  1mm;	  number	  of	  slices	  =	  3.	  For	  T2	  maps,	  the	  images	  
were	  acquired	  using	  a	  multispin	  multiecho	  (MSME)	  with	  the	  following	  parameter:	  
TR/TE=	  3000/18	  ms,	  number	  of	  echoes=8	  with	  TE	  spacing	  =18ms,	  matrix	  size=	  
128×128;	  FOV	  =	  32×32	  mm;	  slice	  thickness	  =	  1mm.	  The	  image	  intensities,	  T2	  maps	  
and	  values	  were	  obtained	  using	  home-­‐written	  Matlab	  (Natick,	  MA)	  software.	  
To	  verify	  the	  potential	  of	  cell	  tracking	  on	  a	  clinically	  relevant	  substrate,	  
biodegradable	  scaffolds	  seeded	  with	  USPIO	  labeled	  macrophages	  and	  controls	  were	  
imaged	  using	  the	  same	  MRI	  sequences	  above.	  The	  controls	  consisted	  of	  a	  scaffold	  
seeded	  with	  unlabeled	  macrophages	  and	  an	  unseeded	  scaffold.	  	  
	  
Cell	  Labeling	  and	  Suspension	  
In	  order	  to	  determine	  the	  cellular	  limit	  of	  detection	  of	  USPIO-­‐labeled	  macrophages	  
MRI	  phantom	  imaging	  of	  known	  numbers	  of	  labeled	  cells	  was	  performed.	  
Macrophages	  were	  grown	  to	  confluency	  in	  a	  T75	  flask	  and	  incubated	  with	  2	  mg/ml	  
of	  USPIO	  nanoparticles	  for	  36	  hours	  in	  SFM.	  Labeled	  cells	  were	  then	  collected,	  
counted,	  and	  fixed	  in	  10%	  neutral	  buffered	  formalin	  (NBF;	  Sigma-­‐Aldrich)	  
overnight.	  Following	  fixation,	  labeled	  cells	  were	  homogenously	  suspended	  in	  
Histogel®	  (Richard-­‐Allan	  Scientific,	  Kalama-­‐	  zoo,	  MI,	  USA)	  in	  the	  following	  known	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quantities:	  25x106,	  20x106,	  15x106,	  10x106,	  5x106,	  and	  1x106.	  The	  known	  cell	  
numbers	  were	  suspended	  in	  500	  μl	  of	  PBS	  using	  Corning®	  96	  Well	  Polypropylene	  
Cluster	  Tubes	  and	  then	  500	  μl	  of	  Histogel	  was	  added	  pipetting	  up	  and	  down	  to	  
ensure	  the	  cells	  were	  homogenously	  suspended.	  Controls	  consisted	  of	  samples	  
without	  cells	  and	  samples	  with	  unlabeled	  cells.	  	  
The	  cellular	  limit	  of	  detection	  was	  determined	  by	  analyzing	  the	  T2	  maps	  of	  the	  
cellular	  suspensions.	  The	  number	  of	  cells	  in	  each	  1	  mm	  slice	  of	  the	  homogenous	  cell	  
suspension	  was	  determined	  by	  calculating	  the	  volume	  of	  the	  cylindrical	  tube	  used	  
for	  the	  MRI	  (height	  =	  1	  mm,	  radius	  =	  3.5	  mm).	  This	  number	  corresponded	  to	  a	  given	  
T2	  value	  for	  each	  sample.	  
	  
Scaffold	  Suspensions	  
Prior	  to	  in	  vivo	  application,	  it	  was	  important	  to	  image	  a	  TEVG	  seeded	  with	  USPIO	  
labeled	  macrophages	  in	  order	  to	  confirm	  the	  potential	  for	  cell	  tracking	  on	  a	  
clinically	  relevant	  substrate.	  Biodegradable	  scaffolds	  were	  seeded	  with	  USPIO	  
labeled	  macrophages	  and	  unlabeled	  macrophages	  as	  previously	  described.	  On	  day	  1	  
post	  seeding,	  the	  seeded	  scaffolds	  were	  suspended	  in	  Histogel	  (BD	  Biosciences,	  San	  
Jose,	  CA,	  USA)	  in	  Corning®	  96	  Well	  Polypropylene	  Cluster	  Tubes.	  As	  controls,	  one	  
tube	  was	  filled	  with	  Histogel	  and	  one	  contained	  an	  unlabeled	  scaffold.	  MR	  imaging	  







In	  vivo	  MRI	  
For	  in	  vivo	  MRI,	  Mice	  with	  seeded	  labeled	  or	  seeded	  unlabeled	  scaffolds	  were	  
anesthetized	  with	  1.5	  %	  isoflurane	  and	  imaged	  immediately	  after	  the	  implantation	  
every	  30	  min	  for	  9	  h.	  On	  post-­‐operative	  day	  7,	  mice	  were	  again	  anesthetized	  and	  
maintained	  on	  isoflurane	  for	  imaging.	  For	  T2	  weighted	  images,	  the	  images	  were	  
acquired	  using	  a	  rapid	  acquisition	  with	  relaxation	  enhancement	  spin-­‐echo	  sequence	  
(RARE).	  Imaging	  parameters	  were	  as	  follows:	  field	  of	  view	  =	  28	  mm,	  image	  matrix	  =	  
128	  ×	  128,	  slice	  thickness	  =	  1	  mm,	  RARE	  factor	  =	  4,	  effective	  echo	  time	  =	  34	  ms	  and	  
recycle	  time	  =	  4	  s.	  For	  T2	  maps,	  (MSME)	  sequence	  was	  used	  with	  the	  following	  
parameters:	  Number	  of	  echoes=6	  and	  echo	  spacing	  =17	  ms,	  TR/TE	  =4000/17	  ms,	  
field	  of	  view	  =	  28	  mm,	  image	  matrix	  =	  128	  ×	  128,	  slice	  thickness	  =	  1	  mm.	  T2	  maps	  
were	  generated	  by	  pixel-­‐by	  pixel	  fitting	  using	  home-­‐written	  Matlab	  6.5.2	  (The	  Math	  
Works,	  Inc,	  USA)	  	  
	  
Implantation	  of	  Biodegradable	  Scaffolds	  
	  
Anesthesia	  was	  induced	  by	  inhalation	  of	  4%	  vaporized	  isoflurane	  in	  a	  mixture	  of	  
oxygen.	  During	  surgical	  procedure,	  isoflurane	  was	  maintained	  in	  0.5-­‐1.5	  %	  without	  
any	  clinical	  signs	  of	  pain	  or	  changes	  of	  macrohemodynamic	  parameters.	  For	  the	  
animals	  undergoing	  surgery	  for	  postmortem	  MR	  analysis,	  xylazine/ketamine	  
anesthesia	  was	  used	  instead.	  These	  animals	  were	  anesthetized	  with	  intraperitoneal	  
injection	  made	  by	  mixing	  1.5	  ml	  of	  100	  mg/ml	  xylazine	  (Sigma-­‐Aldrich)	  and	  10	  ml	  of	  
100	  mg/ml	  ketamine	  (Sigma-­‐	  Aldrich)	  diluted	  in	  a	  ratio	  of	  1:4	  with	  0.9%	  normal	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saline	  and	  injected	  at	  a	  dose	  of	  0.1	  ml/20	  g	  of	  body	  weight.	  Upon	  induction	  of	  
anesthesia	  the	  animals	  were	  placed	  in	  a	  supine	  position.	  	  Using	  an	  X18	  dissecting	  
microscope	  (Zeiss,	  Thornwood,	  NY,	  USA),	  a	  midline	  laparotomy	  was	  performed,	  and	  
the	  abdominal	  viscera	  were	  lateralized	  to	  allow	  visualization	  of	  the	  abdominal	  aorta.	  
Care	  was	  taken	  to	  separate	  the	  aorta	  from	  the	  vena	  cava.	  Proximal	  and	  distal	  
vascular	  control	  of	  the	  vessels	  was	  obtained	  below	  the	  renal	  vessels	  and	  above	  the	  
iliac	  bifurcation.	  The	  open	  abdominal	  cavity	  was	  bathed	  in	  warmed	  (37°C)	  
heparinized	  saline	  (250	  U/ml).	  The	  native	  vessel	  was	  gently	  occluded	  with	  
removable	  microvascular	  clamps	  and	  then	  transected.	  Anastamosis	  to	  a	  caliber-­‐
matched	  TEVG	  (1	  mm	  diameter)	  was	  performed	  at	  the	  infrarenal	  level	  of	  	  the	  IVC	  
using	  interrupted	  10-­‐0	  monofilament	  nylon	  (Sharpoint	  Lab	  Sutures,	  Calgary,	  AB,	  
Can-­‐	  ada).	  On	  completion	  of	  the	  distal	  anastamosis,	  the	  midline	  incision	  was	  closed	  
with	  running	  5-­‐0	  prolene	  sutures.	  After	  laparotomy	  closure,	  animals	  were	  
monitored	  during	  recovery	  and	  placed	  on	  a	  warm	  pad	  to	  avoid	  hypothermia.	  The	  
animals	  recovered	  from	  surgery	  and	  were	  maintained	  without	  the	  use	  of	  any	  anti-­‐
coagulation	  or	  anti-­‐platelet	  therapy.	  	  
Animal	  handling	  was	  in	  accordance	  with	  the	  institutional	  guidelines	  for	  the	  use	  and	  
care	  of	  animals,	  and	  the	  institutional	  review	  board	  approved	  the	  experimental	  
procedures.	  	  
	  
Postmortem	  MR	  imaging	  
	  
Postmortem	  imaging	  was	  performed	  with	  USPIO	  labeled	  scaffold	  implants	  
immediately	  after	  implantation	  and	  one-­‐week	  post-­‐implantation	  as	  proof	  of	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principle	  for	  serial	  imaging.	  USPIO-­‐labeled	  and	  unlabeled	  macrophages	  were	  seeded	  
onto	  biodegradable	  polymer	  scaffolds	  that	  were	  then	  implanted	  as	  interposition	  
grafts	  in	  the	  Inferior	  Vena	  Cavas	  (IVC)	  of	  female	  C.B-­‐17	  SCID/bg	  mice.	  Two	  mice	  
with	  USPIO-­‐labeled	  scaffold	  implants	  and	  two	  mice	  with	  unlabeled	  scaffold	  implants	  
were	  euthanized	  by	  CO2	  asphyxiation	  immediately	  following	  surgical	  implantation	  
and	  underwent	  postmortem	  imaging.	  Two	  mice	  with	  USPIO-­‐labeled	  scaffold	  
implants	  and	  two	  mice	  with	  unlabeled	  scaffold	  implants	  were	  resuscitated	  after	  the	  
surgical	  implantation	  and	  euthanized	  7	  days	  later	  for	  postmortem	  imaging.	  	  
Histologic	  analysis	  
All	  infrarenal	  IVC	  scaffolds	  were	  explanted	  and	  fixed	  in	  10%	  neutral	  buffered	  
formalin	  (NBF;	  Sigma-­‐Aldrich)	  overnight	  prior	  to	  histological	  embedding	  with	  
glycolmethacrylate	  (GMA).	  GMA-­‐embedded	  samples	  were	  stained	  with	  Lee’s	  
methylene	  blue	  (a	  substitute	  for	  traditional	  hematoxylin	  and	  eosin	  (H&E)	  staining)	  
with	  a	  nuclear	  red	  counterstain.	  Scaffolds	  were	  stained	  for	  the	  presence	  of	  
intracellular	  iron	  with	  Prussian	  blue	  as	  previously	  described.	  	  
(Scaffold	  explantation	  and	  tissue	  fixation	  was	  perfomed	  by	  Jamie	  K.	  Harrington;	  
Sample	  embedding	  was	  performed	  by	  Nancy	  Troiano;	  Tissue	  staining	  was	  
performed	  by	  both	  Jamie	  K.	  Harrington	  and	  Nancy	  Troiano)	  
Cell	  Counting	  
Two	  separate	  sections	  of	  each	  scaffold	  explant	  were	  stained	  with	  H&E	  and	  Prussian	  
blue	  and	  imaged	  at	  a	  magnification	  of	  400x.	  The	  number	  of	  nuclei	  were	  counted	  in	  
four	  regions	  of	  each	  section	  and	  averaged	  to	  determine	  total	  cellularity.	  The	  number	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of	  cells	  staining	  positive	  for	  Prussian	  blue	  were	  counted	  in	  four	  regions	  of	  each	  
section	  and	  averaged	  to	  determine	  total	  number	  of	  cells	  containing	  USPIO	  
nanoparticles.	  	  
(Performed	  by	  Jamie	  K.	  Harrington)	  
Statistical	  Analysis	  
Statistical	  differences	  were	  analyzed	  with	  paired	  and	  unpaired	  Student's	  t	  tests	  or	  
ANOVAs.	  P	  <	  0.05	  was	  considered	  statistically	  significant.	  


















Optimization	  of	  Macrophage	  Labeling	  with	  USPIO	  and	  Scaffold	  Seeding	  
Raw	  264.7	  murine	  macrophage/monocyte	  cell	  line	  was	  utilized	  for	  all	  
experiments	  based	  on	  prior	  analysis	  by	  our	  lab	  showing	  that	  the	  bone	  marrow	  cell	  
population	  used	  for	  scaffold	  seeding	  is	  composed	  predominantly	  of	  monocytes	  (33)	  
and	  well-­‐established	  evidence	  that	  macrophages	  are	  ideal	  for	  MRI	  contrast	  cell	  
labeling	  and	  in	  vivo	  cell	  tracking	  (80-­‐82).	  
The	  first	  objective	  of	  this	  study	  was	  to	  determine	  an	  optimal	  condition	  to	  
achieve	  adequate	  in	  vitro	  cell	  labeling	  of	  the	  macrophage	  cell	  line.	  In	  order	  to	  
determine	  these	  conditions,	  macrophages	  were	  incubated	  with	  various	  
concentrations	  of	  both	  poly-­‐l-­‐lysine	  and	  non-­‐poly-­‐l-­‐lysine	  coated	  USPIO	  
nanoparticles	  for	  various	  incubation	  durations	  (data	  not	  shown).	  	  Based	  on	  labeling	  
efficiency	  determination	  and	  cellular	  and	  metabolic	  viability	  studies	  the	  conditions	  
were	  optimized	  using	  non-­‐poly-­‐l-­‐lysine	  coated	  USPIO	  nanoparticles	  at	  a	  
concentration	  of	  2	  mg/ml	  for	  an	  incubation	  duration	  of	  36	  hours	  in	  serum	  free	  
culture	  medium	  (SFM).	  Serum	  free	  culture	  medium	  was	  used	  for	  all	  studies	  based	  
on	  evidence	  that	  proteins	  in	  the	  serum	  chelate	  the	  iron	  oxide	  particles	  and	  interfere	  
with	  cellular	  uptake	  e(80).	  After	  cell	  labeling	  at	  these	  conditions	  Prussian	  blue	  
staining	  to	  reveal	  intracellular	  iron	  deposits	  consistently	  showed	  a	  robust	  labeling	  
efficiency	  (Figure	  1A,	  B).	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Figure	  1.	  Evaluation	  of	  USPIO	  cell	  labeling	  and	  scaffold	  cell	  seeding.	  Murine	  
macrophages	  were	  stained	  with	  prussian	  blue	  to	  identify	  intracellular	  iron.	  (A)	  
Photomicrograph	  of	  unlabeled	  control	  macrophages	  (H&E,	  400x)	  	  (B)	  
Photomicrograph	  of	  macrophages	  after	  USPIO	  cell	  labeling	  (H&E,	  400x).	  (C)	  
Photomicrograph	  of	  USPIO	  labeled	  macrophages	  statically	  seeded	  onto	  a	  
biodegradable	  scaffold	  (Lee's	  methylene	  blue,	  40x).	  (D)	  Representative	  section	  of	  
the	  same	  seeded	  scaffold	  showing	  the	  PGA	  scaffold	  fibers	  (arrowhead)	  and	  the	  
USPIO-­‐labeled	  macrophages	  (arrow)	  (Lee's	  methylene	  blue,	  400x).	  	  
	  
The	  metabolic	  activity	  and	  the	  cellular	  viability	  of	  the	  labeled	  macrophages	  
as	  measured	  using	  the	  MTS	  assay	  and	  Flow	  Cytometry,	  respectively,	  were	  not	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statistically	  different	  from	  control	  macrophages	  (receiving	  a	  USPIO	  concentration	  of	  
0	  mg/ml)	  (Table	  1).	  	  
	  
	  
Table	  1.	  Cell	  viability	  and	  Metabolic	  Activity	  of	  USPIO-­labeled	  macrophages	  	  	  
	  
USPIO	  Concentration	   2	  mg/mL	   0	  mg/mL	   p-­‐value	  
Metabolic	  Activity	  (n=	  6)	   2.99	  ±	  0.10	   3.22	  ±	  0.06	   0.08	  
Cellular	  Viability	  (n=	  7)	   63.58	  	  ±	  0.89	   62.99	  ±	  2.37	   0.82	  
Values	  are	  expressed	  as	  the	  mean	  ±	  SEM.	  
	  
Once	  robust	  cell	  labeling	  was	  achieved	  without	  affecting	  cellular	  metabolism	  
or	  viability,	  the	  static	  seeding	  efficiency	  of	  the	  USPIO-­‐labeled	  macrophages	  onto	  our	  
PGA	  biodegradable	  polymer	  scaffolds	  was	  determined.	  The	  static	  seeding	  efficiency	  
for	  the	  macrophage	  cell	  line	  was	  found	  to	  be	  approximately	  8%.	  This	  is	  consistent	  
with	  other	  studies	  that	  consistently	  show	  a	  seeding	  efficiency	  between	  5-­‐10%	  
depending	  on	  the	  cell	  line	  being	  used	  (72).	  With	  this	  seeding	  efficiency,	  five	  million	  
macrophages	  could	  be	  statically	  seeded	  onto	  each	  scaffold	  resulting	  in	  retention	  of	  
approximately	  3.8	  x	  105	  ±	  13%	  cells.	  This	  was	  found	  to	  be	  optimal	  for	  all	  
experiments.	  Histological	  sections	  of	  the	  scaffolds	  after	  static	  seeding	  and	  cell	  
culture	  with	  the	  USPIO-­‐labeled	  macrophages	  showed	  the	  seeded	  macrophages	  were	  
able	  to	  penetrate	  the	  pores	  of	  the	  PGA	  mesh	  and	  were	  able	  to	  remain	  well	  infiltrated	  
into	  the	  walls	  and	  attached	  to	  the	  lumen	  and	  exterior	  of	  the	  scaffolds	  even	  after	  
scaffold	  manipulation	  (Figure	  1C,	  D).	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In	  vitro	  MRI	  Analysis	  
The	  next	  objective	  in	  the	  study	  was	  to	  perform	  an	  in	  vitro	  characterization	  of	  
the	  USPIO-­‐labeled	  macrophages	  and	  the	  USPIO-­‐labeled	  macrophage	  seeded	  
scaffolds	  by	  MR	  imaging.	  Labeled	  macrophages	  were	  homogeneously	  suspended	  in	  
Histogel®	  in	  seven	  serial	  dilutions	  from	  25x106	  to	  0	  cells	  per	  1	  mL	  of	  Histogel®	  
suspension.	  	  T2	  weighted-­‐images	  were	  then	  acquired	  using	  a	  spin-­‐echo	  sequence.	  	  
As	  the	  number	  of	  labeled	  cells	  increased,	  the	  T2	  signal	  intensity	  dropped	  (Figure	  
2A)	  and	  the	  T2	  values	  gradually	  decreased	  (Figure	  2B	  and	  Table	  2).	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Figure	  2.	  In	  vitro	  Characterization	  of	  USPIO-­labeled	  macrophages	  and	  seeded	  
scaffolds.	  (A)	  T2	  weighted	  image	  of	  a	  gelatin	  phantom	  using	  an	  array	  of	  
concentration	  gradients	  of	  USPIO	  labeled	  macrophages:	  A=	  25x106,	  B=	  20x106,	  C=	  
15x106,	  D=	  10x106,	  E=	  5x106,	  	  F=	  106	  and	  G=	  0	  labeled	  cells	  	  (B)	  T2	  mapping	  of	  the	  
same	  sample.	  (C)	  In	  vitro	  T2	  weighted	  image	  of	  an	  unlabeled	  scaffold,	  unseeded	  
scaffold	  and	  a	  USPIO-­‐labeled	  scaffold	  suspended	  in	  gelatin.	  (D)	  T2	  mapping	  of	  the	  










Table	  2.	  In	  vitro	  T2	  values	  of	  USPIO	  labeled	  macrophages.	  
	  
Sample	   Cell	  Number	  in	  1	  mm	  slice	   T2	  Value	  (ms)	  
A	  (25x106)	   882,080	   (out	  of	  range)	  
B	  (20x106)	   705,664	   15.4	  
C	  (15x106)	   529,248	   16.5	  
D	  (10x106)	   352,832	   22	  
E	  (5x106)	   176,416	   48	  
F	  (1x106)	  §	   35,283	   140	  
G	  (Control)	  §	   0	   202	  
§	  below	  the	  limit	  of	  detection	  
	  
	  
Table	  3.	  In	  vitro	  T2	  values	  of	  scaffolds	  seeded	  with	  USPIO	  labeled	  
macrophages.	  
	  
Scaffold	   T2	  Value	  (ms)	  
USPIO-­‐Labeled	   	  26.66	  
Non-­‐USPIO-­‐Labeled	   45.38	  
Unseeded	   84.5	  
	  
	  
USPIO	  is	  a	  T2	  contrast	  agent	  that	  shortens	  T2	  relaxation	  times	  resulting	  in	  a	  
negative	  image	  with	  a	  hypodense	  signal,	  resulting	  in	  a	  darker	  appearance	  of	  the	  
image	  with	  increasing	  amounts	  of	  iron-­‐oxide	  in	  the	  sample.	  The	  T2	  values	  were	  
calculated	  for	  each	  1	  mm	  slice	  and	  based	  on	  known	  cell	  numbers	  in	  each	  1	  mm	  MRI	  
slice,	  the	  T2	  value	  could	  be	  correlated	  with	  a	  given	  number	  of	  USPIO	  labeled	  
macrophages.	  The	  T2	  values	  ranged	  from	  202	  ms	  for	  the	  gelatin	  phantom	  without	  
any	  USPIO	  labeled	  macrophages	  to	  15.4	  ms	  for	  the	  sample	  with	  20x106	  
macrophages	  (the	  sample	  with	  the	  highest	  amount	  of	  iron	  oxide	  that	  was	  still	  in	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signal	  range).	  Although	  the	  T2	  values	  gradually	  increased	  for	  samples	  B	  through	  E	  
as	  the	  cell	  number	  decreased	  from	  20x106	  (~700,000	  cells/1	  mm	  slice)	  to	  5x106	  
(~175,000	  cells/1	  mm	  slice)	  the	  T2	  values	  were	  consistently	  low	  compared	  to	  the	  
gelatin	  phantom	  that	  did	  not	  contain	  any	  iron-­‐oxide,	  ranging	  between	  15.4	  ms	  and	  
48	  ms.	  It	  is	  not	  until	  the	  cell	  number	  decreases	  to	  1x106	  (~35,000	  cells/1	  mm	  slice)	  
that	  the	  T2	  value	  shows	  a	  significant	  increase	  to	  140	  ms.	  In	  other	  words,	  sample	  E	  is	  
the	  first	  concentration	  of	  iron	  oxide	  where	  the	  signal	  void	  (T2	  shortening)	  begins	  to	  
become	  apparent	  compared	  to	  sample	  F	  and	  G	  (the	  control).	  Based	  on	  these	  T2	  
values	  the	  cellular	  limit	  of	  detection	  was	  determined	  to	  be	  between	  175,000	  and	  
35,000	  cells.	  This	  detection	  limit	  fell	  well	  below	  the	  macrophage	  retention	  number	  
after	  static	  seeding	  	  (~3.8	  x	  105	  ±	  13%	  cells)	  providing	  evidence	  for	  the	  feasibility	  of	  
MRI	  detection	  on	  our	  biodegradable	  scaffolds.	  	  
Next,	  to	  confirm	  the	  potential	  for	  cell	  tracking	  on	  a	  clinically	  relevant	  
substrate,	  USPIO	  labeled	  macrophages	  were	  seeded	  onto	  biodegradable	  scaffolds	  for	  
in	  vitro	  MRI	  analysis.	  Three	  scaffolds	  were	  suspended	  in	  Histogel®	  for	  MRI	  analysis	  
and	  T2	  mapping,	  one	  scaffold	  seeded	  with	  UPSIO	  labeled	  macrophages,	  one	  scaffold	  
seeded	  with	  unlabeled	  macrophages,	  and	  one	  unseeded	  scaffold	  (Figure	  2C,	  D).	  The	  
T2	  values	  for	  the	  scaffolds	  were	  26.66	  ms,	  45.38	  ms,	  and	  84.50	  ms,	  respectively	  
(Table	  3).	  The	  region	  of	  signal	  void	  created	  around	  the	  scaffold	  seeded	  with	  labeled	  
macrophages	  was	  significantly	  larger	  than	  the	  void	  created	  by	  the	  scaffold	  seeded	  
with	  unlabeled	  macrophages	  or	  the	  unseeded	  scaffold.	  This	  confirmed	  that	  labeling	  
macrophages	  with	  USPIO	  substantially	  reduced	  the	  MRI	  signal	  intensity	  around	  the	  
scaffold	  making	  it	  appear	  uniformly	  dark	  and	  easily	  detectable	  on	  MRI.	  In	  addition,	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the	  USPIO	  labeled	  scaffold	  appeared	  larger	  than	  either	  of	  the	  other	  scaffolds	  
secondary	  to	  the	  “blooming	  effect,”	  an	  amplification	  of	  signal	  change	  on	  gradient-­‐
echo	  images	  where	  T2	  effects	  dominate,	  which	  increases	  visibility	  on	  MRI.	  	  
Interestingly	  the	  T2	  value	  for	  the	  USPIO	  seeded	  scaffold	  was	  26.66	  ms,	  a	  number	  
that	  closely	  resembles	  the	  T2	  value	  calculated	  for	  the	  USPIO	  cell	  suspension	  
containing	  ~350,000	  cells/1	  mm	  slice	  (22	  ms,	  sample	  D).	  Given	  that	  the	  
macrophage	  retention	  after	  static	  seeding	  is	  approximately	  300,000	  cells	  these	  
numbers	  closely	  correspond	  and	  provide	  further	  evidence	  for	  the	  correlation	  of	  T2	  
values	  with	  cell	  number	  for	  cell	  tracking	  in	  vivo.	  	  
Through	  MR	  phantom	  imaging,	  the	  in	  vitro	  detection	  limit	  for	  USPIO-­‐labeled	  
macrophages	  was	  determined,	  and	  the	  potential	  for	  cell	  tracking	  on	  a	  clinically	  
relevant	  substrate	  was	  demonstrated,	  providing	  the	  necessary	  background	  to	  begin	  
noninvasive	  cell	  tracking	  on	  the	  TEVGs	  in	  vivo	  with	  MR	  imaging.	  	  
	  
In	  vivo	  Serial	  MRI	  Analysis	  and	  Cell	  Tracking	  
For	  in	  vivo	  MRI	  analysis	  four	  SCID/beige	  mice	  were	  surgically	  implanted	  with	  
TEVGs	  seeded	  with	  USPIO-­‐labeled	  macrophages,	  and	  four	  SCID/beige	  mice	  serving	  
as	  controls	  were	  implanted	  with	  TEVGs	  seeded	  with	  unlabeled	  macrophages.	  	  The	  
TEVGs	  were	  implanted	  as	  infrarenal	  interposition	  grafts	  in	  the	  inferior	  vena	  cavas	  
(IVCs)	  of	  the	  mice.	  After	  implantation,	  Rare	  T2	  weighted	  images	  were	  obtained	  
immediately	  postoperatively	  and	  at	  one	  week	  post-­‐implantation	  in	  all	  the	  mice.	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Representative	  Rare	  T2	  weighted	  images	  and	  their	  corresponding	  T2	  maps	  are	  
shown	  in	  Figure	  3.	  	  
	  
Figure	  3.	  In	  vivo	  MR	  Imaging	  of	  Labeled	  and	  Unlabeled	  Scaffold	  Implants.	  
Representative	  axial	  T2	  weighted	  RARE	  images	  of	  mice	  implanted	  with	  (A)	  labeled	  
and	  (B)	  unlabeled	  seeded	  scaffolds,	  illustrating	  the	  location	  of	  implanted	  scaffolds	  
(boxes).	  Kidneys	  (K)	  and	  the	  liver	  (L)	  are	  visible	  in	  the	  images.	  The	  corresponding	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T2	  maps	  of	  the	  same	  slices	  showing	  T2	  value	  differences	  between	  the	  (C)	  labeled	  
and	  (D)	  unlabeled	  seeded	  scaffolds.	  
	  
The	  TEVGs	  were	  easily	  identified	  retroperitoneally	  in	  the	  infrarenal	  IVCs	  of	  
the	  mice,	  both	  immediately	  after	  implantation,	  and	  after	  1	  week.	  T2	  values	  were	  
calculated	  for	  the	  TEVGs	  seeded	  with	  both	  USPIO-­‐labeled	  and	  unlabeled	  
macrophages	  as	  well	  as	  for	  other	  tissues	  including	  the	  liver,	  muscle,	  and	  fat.	  The	  T2	  
values	  measured	  in	  all	  the	  tissues	  outside	  of	  the	  IVC	  implants	  were	  similar	  in	  both	  
groups	  immediately	  after	  implantation	  and	  at	  one	  week	  postimplantation	  (Figure	  
4A,	  B).	  	  
	  
Figure	  4.	  In	  vivo	  T2	  Values	  for	  Serial	  MR	  Imaging	  of	  Scaffold	  Implants.	  T2	  values	  
for	  scaffold	  implants	  and	  extra-­‐vascular	  tissues	  in	  mice	  with	  USPIO-­‐labeled	  implants	  
(dashed	  bars)	  and	  mice	  with	  non-­‐USPIO-­‐labeled	  implants	  (plain	  bars)	  imaged	  (A)	  
immediately	  after	  implantation	  and	  (B)	  one	  week	  post	  implantation.	  To	  gain	  further	  
insight	  into	  the	  temporal	  increase	  in	  the	  T2	  value	  in	  the	  labeled	  scaffolds,	  T2	  values	  
were	  calculated	  for	  scaffold	  implants	  in	  one	  additional	  mouse	  with	  a	  USPIO-­‐labeled	  
implant	  (dark	  dashed	  bars)	  and	  one	  with	  a	  non-­‐USPIO-­‐labeled	  implant	  (plain	  bars)	  
at	  30-­‐minute	  increments	  starting	  immediately	  after	  implantation	  (C).	  	  
	  
The	  T2	  maps	  reveal	  significantly	  lower	  T2	  values	  in	  the	  TEVGs	  seeded	  with	  
USPIO	  labeled	  macrophages	  immediately	  postoperatively	  (T2	  =	  44±6.8	  vs.	  71±10.2),	  
(Figure	  4A)	  that	  was	  no	  longer	  apparent	  at	  7	  days	  post-­‐operatively	  (T2	  =	  63±12	  vs.	  
63±14).	  The	  drop	  in	  the	  T2	  values	  seen	  in	  the	  TEVGs	  seeded	  with	  USPIO-­‐
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macrophages	  verifies	  that	  the	  seeded	  macrophages	  were	  retained	  on	  the	  scaffold	  
after	  surgical	  implantation	  in	  numbers	  greater	  than	  the	  MRI	  cellular	  limit	  of	  
detection,	  and	  that	  large	  enough	  number	  of	  cells	  was	  lost	  from	  the	  scaffold	  by	  one	  
week,	  such	  that	  the	  signal	  difference	  was	  no	  longer	  significantly	  detectable.	  In	  order	  
to	  gain	  further	  insight	  into	  the	  time	  frame	  with	  which	  the	  USPIO	  seeded	  
macrophages	  were	  lost	  from	  the	  scaffold	  implants	  additional	  mice	  were	  serially	  
imaged	  in	  30-­‐minute	  increments	  immediately	  after	  scaffold	  implantation	  for	  up	  to	  9	  
hours.	  	  The	  T2	  values	  were	  calculated	  for	  each	  time	  point	  and	  showed	  a	  rapidly	  
progressive	  increase	  in	  the	  T2	  value	  for	  the	  USPIO-­‐seeded	  scaffold	  (Figure	  4C).	  The	  
T2	  value	  increased	  to	  control	  values	  by	  90	  minutes	  after	  implantation	  indicating	  
that	  the	  cells	  are	  rapidly	  lost	  from	  the	  implanted	  TEVG.	  	  
	  
Histological	  Analysis	  
	   These	  findings	  were	  verified	  with	  histology	  of	  USPIO-­‐labeled	  and	  non-­‐USPIO-­‐
labeled	  TEVG	  explants	  immediately	  after	  implantation	  (T=0),	  at	  two	  hours	  after	  
implantation	  (after	  the	  T2	  value	  is	  shown	  to	  increase	  to	  control	  levels),	  and	  one	  
week	  after	  implantation.	  	  The	  scaffold	  explants	  were	  embedded	  in	  GMA	  and	  stained	  
with	  Prussian	  blue	  to	  identify	  intracellular	  iron	  deposits.	  The	  number	  of	  cells	  
containing	  intracellular	  iron	  deposits	  as	  well	  as	  the	  total	  number	  of	  cells	  in	  each	  
scaffold	  was	  determined	  at	  each	  time	  point	  (Figure	  5).	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Figure	  5.	  Fate	  of	  Seeded	  Cells	  by	  Histological	  Analysis.	  Scaffold	  explants	  were	  
stained	  with	  Prussian	  blue	  to	  identify	  intracellular	  iron	  deposits.	  The	  number	  of	  
Prussian	  blue	  labeled	  cells	  (dashed	  bars)	  and	  the	  total	  number	  of	  cells	  (plain	  bars)	  
(per	  HPF)	  were	  counted	  immediately	  after	  implantation	  (Time=0),	  2	  hours,	  and	  one	  
week	  after	  implantation.	  	  
	  
There	  are	  significantly	  more	  Prussian	  blue	  stained	  USPIO	  labeled	  cells	  
(203.625	  ±	  21.085	  /HPF,	  400x)	  visible	  immediately	  post-­‐implantation	  (T=0)	  than	  
after	  2	  hours	  (45.0	  ±	  3.830/HPF,	  400x)	  or	  one	  week	  (34.333	  ±	  6.098/HPF,	  400x).	  
The	  number	  of	  Prussian	  blue	  stained	  cells	  is	  not	  significantly	  different	  after	  2	  hours	  
or	  one	  week	  post-­‐implantation,	  indicating	  that	  the	  majority	  of	  seeded	  cells	  are	  lost	  
from	  the	  scaffold	  immediately	  after	  implantation	  in	  the	  animal.	  In	  addition,	  the	  total	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number	  of	  cells	  in	  the	  scaffold	  at	  time	  0	  and	  after	  2	  hours	  is	  not	  significantly	  
different	  from	  the	  number	  of	  Prussian	  blue	  labeled	  cells	  at	  these	  time	  points.	  	  
However,	  by	  one	  week	  post-­‐implantation	  the	  total	  number	  of	  cells	  in	  the	  scaffolds	  is	  
significantly	  higher	  than	  the	  number	  of	  Prussian	  blue	  labeled	  cells	  due	  to	  host	  cell	  
infiltration.	  These	  findings	  support	  the	  cellular	  MR	  imaging	  data	  correlating	  the	  
rapid	  increase	  in	  T2	  value	  post-­‐implantation	  to	  the	  rapid	  loss	  of	  seeded	  cells	  from	  



















To	  our	  knowledge,	  this	  study	  is	  one	  of	  the	  first	  applications	  of	  noninvasive	  
MR	  imaging	  to	  study	  the	  process	  of	  neotissue	  development	  in	  TEVGs	  through	  the	  
use	  of	  serial	  imaging	  in	  a	  living	  animal	  model.	  We	  have	  used	  noninvasive	  serial	  MR	  
imaging	  to	  support	  recently	  published	  data	  indicating	  that	  the	  bone	  marrow	  
mononuclear	  cells	  used	  to	  seed	  the	  scaffolds	  pre-­‐implantation	  are	  not	  incorporated	  
into	  the	  neovessel	  as	  previously	  thought	  (17),	  but	  are	  instead	  rapidly	  lost	  from	  the	  
TEVG	  post-­‐implantation	  (33).	  	  
In	  order	  to	  accomplish	  this,	  we	  first	  optimized	  the	  macrophage	  USPIO	  
incubation	  conditions	  in	  order	  to	  achieve	  adequate	  cell	  labeling,	  without	  affecting	  
cellular	  viability	  or	  metabolic	  activity,	  providing	  a	  reasonable	  cellular	  limit	  of	  
detection	  on	  our	  scaffolds	  both	  in	  vitro	  and	  in	  vivo	  by	  MRI.	  	  This	  was	  accomplished	  
using	  USPIO	  nanoparticles	  without	  poly-­‐l-­‐lysine	  on	  their	  surface.	  Poly-­‐l-­‐lysine	  has	  
traditionally	  been	  used	  in	  the	  field	  of	  cellular	  MRI	  to	  enhance	  the	  uptake	  of	  the	  MR	  
contrast	  agents	  into	  various	  cell	  types	  by	  changing	  the	  surface	  charge	  of	  the	  
particles.	  This,	  however,	  comes	  at	  the	  cost	  of	  increasing	  cellular	  toxicity	  of	  the	  
nanoparticles	  (55).	  We	  found	  that	  while	  the	  use	  of	  poly-­‐l-­‐lysine	  shortened	  the	  
incubation	  duration	  required	  to	  achieve	  100%	  labeling	  efficiency,	  it	  had	  the	  adverse	  
affect	  of	  impairing	  cellular	  metabolic	  activity	  and	  viability	  as	  determined	  by	  the	  MTS	  
assay	  and	  7-­‐AAD	  flow	  cytometry	  when	  compared	  to	  unlabeled	  cells	  (data	  not	  
shown).	  In	  the	  cell	  population	  composed	  entirely	  of	  macrophages	  and	  monocytes,	  
which	  are	  traditionally	  known	  to	  robustly	  engulf	  MR	  contrast	  agents	  without	  the	  
added	  help	  of	  poly-­‐l-­‐lysine	  (58,80),	  it	  was	  determined	  that	  adequate	  cell	  labeling	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could	  be	  achieved	  without	  poly-­‐l-­‐lysine.	  We	  found	  that	  incubating	  the	  macrophages	  
with	  a	  USPIO	  concentration	  of	  2	  mg/ml	  for	  36	  hours	  in	  serum	  free	  media	  resulted	  in	  
100%	  labeling	  efficiency	  without	  affecting	  cellular	  metabolic	  activity	  or	  viability.	  
This	  is	  consistent	  with	  previous	  investigations	  in	  macrophage	  and	  monocyte	  cell	  
lines	  that	  have	  found	  no	  significant	  toxic	  effects	  with	  a	  labeling	  concentration	  as	  
high	  as	  10mg/ml	  of	  USPIO	  (80).	  
Using	  these	  labeling	  conditions	  we	  were	  able	  to	  perform	  a	  limit	  of	  detection	  
study	  to	  correlate	  USPIO	  labeled	  macrophage	  concentration	  with	  MR	  signal	  
intensity.	  Serially	  diluted	  USPIO	  labeled	  cell	  suspensions	  were	  imaged	  and	  T2	  
mapping	  was	  performed.	  Since	  USPIO	  is	  a	  T2	  contrast	  agent	  it	  creates	  a	  signal	  void	  
or	  a	  hypodense	  change	  in	  signal	  intensity.	  As	  the	  concentration	  of	  USPIO	  labeled	  
macrophages	  was	  incrementally	  increased	  the	  cell-­‐suspension	  samples	  appeared	  
increasingly	  darker	  with	  increasingly	  lower	  T2	  values.	  Through	  an	  analysis	  of	  the	  
quantitative	  T2	  values	  we	  were	  able	  to	  correlate	  the	  USPIO	  labeled	  macrophage	  
concentration	  with	  the	  T2	  values	  and	  determined	  a	  limit	  of	  detection	  for	  our	  labeled	  
cell	  population.	  This	  was	  based	  on	  the	  first	  detectable	  signal	  void	  or	  T2	  shortening	  
that	  occurred	  in	  one	  of	  our	  cell	  suspension	  samples	  compared	  to	  the	  control	  sample.	  
The	  limit	  of	  detection	  was	  found	  to	  be	  between	  175,000	  and	  35,000	  cells.	  This	  is	  
similar	  to	  the	  detection	  threshold	  of	  approximately	  105	  cells	  that	  is	  commonly	  cited	  
in	  other	  literature	  looking	  at	  in	  vivo	  applications	  of	  USPIO	  cell	  tracking	  (44,83,84).	  	  
This	  limit	  of	  detection	  threshold	  is	  dependent	  on	  several	  imaging	  parameters	  such	  
as	  the	  spatial	  and	  temporal	  resolution	  and	  the	  magnetic	  field	  strength.	  Additionally,	  
when	  the	  studies	  are	  being	  performed	  in	  vivo,	  there	  is	  the	  added	  complication	  of	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motion	  artifact	  that	  occurs	  with	  the	  respiratory	  rate	  and	  the	  heart	  rate.	  Under	  ideal	  
conditions	  and	  in	  organs	  where	  motion	  can	  almost	  be	  completely	  eliminated,	  such	  
as	  in	  the	  brain,	  single	  cell	  detection	  has	  become	  possible	  (44,85-­‐87).	  	  However,	  the	  
field	  is	  still	  working	  towards	  this	  becoming	  a	  routine	  capability	  for	  use	  with	  in	  vivo	  
models	  of	  cellular	  MRI.	  For	  our	  model	  of	  vascular	  tissue	  engineering	  and	  TEVG	  
development,	  the	  detection	  limit	  is	  exactly	  what	  would	  be	  expected	  for	  an	  in	  vivo	  
application	  dealing	  with	  an	  active	  circulating	  system	  and	  respiration.	  	  
It	  was	  also	  important	  to	  image	  grafts	  seeded	  with	  USPIO	  labeled	  
macrophages	  to	  determine	  the	  potential	  for	  cell	  tracking	  on	  a	  clinically	  relevant	  
substrate,	  and	  to	  allow	  cell	  concentration	  on	  the	  graft	  to	  be	  correlated	  with	  MR	  
signal	  intensity.	  With	  a	  seeding	  efficiency	  of	  approximately	  8%,	  we	  were	  able	  to	  
effectively	  seed	  our	  biodegradable	  TEVG	  scaffolds	  with	  sufficient	  numbers	  of	  USPIO	  
labeled	  macrophages	  to	  allow	  for	  in	  vitro	  quantification	  by	  MR	  imaging	  and	  T2	  
mapping.	  The	  scaffold	  seeded	  with	  USPIO-­‐labeled	  macrophages	  appeared	  larger	  and	  
darker	  than	  the	  scaffold	  seeded	  with	  unlabeled	  macrophages	  and	  had	  a	  remarkable	  
decrease	  in	  T2	  relaxivity	  due	  to	  the	  presence	  of	  iron	  oxide.	  The	  reason	  the	  USPIO	  
labeled	  scaffold	  appeared	  larger	  than	  the	  unlabeled	  scaffold	  is	  due	  to	  the	  large	  
magnetic	  susceptibility	  of	  iron	  oxide	  particles.	  This	  susceptibility	  can	  affect	  an	  area	  
much	  larger	  than	  the	  actual	  size	  of	  the	  particles,	  leading	  to	  an	  exaggeration	  of	  the	  
region	  occupied	  by	  iron	  oxide.	  This	  is	  referred	  to	  as	  the	  ”blooming	  effect,”	  an	  
amplification	  of	  signal	  changes	  produced	  by	  microscopic	  inhomogeneities	  in	  the	  
magnetic	  field	  that	  produce	  a	  rapid	  dephasing	  of	  diffusing	  water	  protons	  including	  
those	  some	  distance	  away	  leading	  to	  a	  hypointense	  effect	  that	  extends	  beyond	  the	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individual	  particles	  (42,47).	  This	  is	  a	  commonly	  cited	  disadvantage	  to	  the	  use	  of	  iron	  
oxide	  for	  cellular	  MRI.	  	  However,	  in	  our	  current	  application	  the	  blooming	  effect	  has	  
actually	  been	  beneficial	  in	  allowing	  for	  an	  increased	  sensitivity	  of	  detection	  of	  
TEVGs	  within	  the	  native	  vessel	  background.	  	  
For	  the	  in	  vivo	  application,	  USPIO	  labeled	  biodegradable	  scaffolds	  were	  
implanted	  as	  infrarenal	  interposition	  grafts	  in	  the	  inferior	  vena	  cavas	  of	  SCID/bg	  
mice.	  T2	  mapping	  of	  the	  IVC	  scaffold	  implants	  showed	  a	  drop	  in	  T2	  signal	  intensity	  
immediately	  after	  implantation	  that	  was	  no	  longer	  observed	  at	  either	  2	  hours	  or	  1	  
week	  post-­‐implantation.	  	  In	  order	  to	  get	  a	  better	  temporal	  picture	  of	  the	  frequency	  
with	  which	  the	  USPIO-­‐labeled	  cells	  were	  lost	  from	  the	  implanted	  scaffold,	  we	  
performed	  serial	  images	  on	  a	  mouse	  with	  a	  USPIO-­‐labeled	  implant	  every	  30	  
minutes,	  until	  the	  T2	  signal	  had	  increased	  to	  values	  seen	  in	  control	  mice	  with	  
unlabeled	  implants.	  The	  T2	  signal	  increased	  to	  control	  levels	  within	  90	  minutes	  of	  
implantation.	  This	  rapid	  increase	  in	  T2	  signal	  intensity	  correlates	  with	  the	  loss	  of	  
USPIO	  labeled	  cells	  from	  the	  scaffolds.	  To	  verify	  our	  findings,	  TEVGs	  were	  explanted	  
and	  stained	  with	  Prussian	  blue	  for	  the	  presence	  of	  iron	  oxide	  labeled	  cells.	  The	  
number	  of	  iron	  oxide	  labeled	  cells	  decreases	  significantly	  as	  early	  as	  two	  hours	  post-­‐
implantation.	  The	  number	  of	  iron	  oxide	  labeled	  cells	  is	  not	  statistically	  different	  
from	  two	  hours	  to	  one	  week	  post-­‐implantation,	  leading	  us	  to	  believe	  that	  all	  of	  the	  
iron	  oxide	  labeled	  cells	  are	  lost	  from	  the	  implanted	  scaffold	  immediately	  after	  
implantation.	  	  This	  corresponds	  very	  nicely	  with	  the	  rapid	  rise	  in	  the	  T2	  value	  at	  2	  
hours	  post-­‐implantation.	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This	  data	  supports	  the	  recently	  published	  data	  by	  Roh	  et	  al.	  (33)	  showing	  
that	  by	  one	  week	  post-­‐implantation,	  there	  are	  no	  longer	  any	  seeded	  human	  BMCs	  
detectable	  in	  the	  neovessel.	  Roh	  et	  al.	  concluded	  that,	  in	  contrast	  to	  prior	  studies	  
reporting	  that	  the	  seeded	  BMCs	  gave	  rise	  to	  the	  cells	  of	  the	  neovessel,	  the	  seeded	  
cells	  are	  rapidly	  lost	  from	  the	  implanted	  TEVG.	  Here,	  we	  have	  verified	  this	  same	  
data	  by	  utilizing	  cellular	  MRI	  to	  track	  the	  fate	  of	  the	  seeded	  cells	  in	  our	  small	  animal	  
model	  of	  TEVG	  development.	  This	  data	  is	  consistent	  with	  the	  new	  inflammatory-­‐
mediated	  model	  of	  vascular	  remodeling.	  This	  model	  hypothesizes	  that	  the	  process	  
of	  neovessel	  formation	  is	  not	  driven	  by	  stem	  cells	  within	  the	  seeded	  BMC	  population	  
differentiating	  into	  mature	  cells	  of	  the	  neovessel,	  but	  that	  instead	  the	  seeded	  BMCs	  
are	  responsible	  for	  secreting	  a	  host	  of	  inflammatory	  mediators	  that	  recruit	  host	  
inflammatory	  cells	  to	  the	  TEVG	  that	  initiates	  an	  inflammation	  driven	  process	  of	  
neovessel	  formation.	  Not	  only	  do	  these	  findings	  provide	  additional	  evidence	  for	  this	  
novel	  school	  of	  thought	  about	  the	  mechanism	  of	  neotissue	  development	  in	  TEVGs,	  
but	  these	  answers	  to	  critical	  questions	  regarding	  neovessel	  formation	  were	  
obtained	  by	  utilizing	  cellular	  MRI,	  a	  noninvasive	  in	  vivo	  technique.	  
One	  major	  limitation	  in	  the	  field	  of	  tissue	  engineering	  is	  the	  lack	  of	  advanced	  
analytical	  tools,	  especially	  those	  that	  allow	  noninvasive	  monitoring	  of	  tissue	  
development.	  Currently,	  the	  most	  widely	  used	  method	  for	  characterizing	  tissue	  
engineered	  constructs	  consists	  of	  sacrificing	  the	  animal	  host,	  harvesting	  the	  
construct,	  and	  performing	  histology.	  This	  approach	  results	  in	  the	  destruction	  of	  the	  
sample	  and	  precludes	  longitudinal	  studies	  with	  the	  same	  tissue	  engineered	  samples	  
(51).	  	  To	  overcome	  this	  problem,	  many	  groups	  have	  begun	  to	  focus	  on	  incorporating	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noninvasive	  cellular	  MR	  imaging	  techniques	  to	  study	  their	  tissue-­‐engineering	  
applications.	  Although	  the	  use	  of	  molecular	  and	  cellular	  MRI	  is	  still	  very	  limited	  in	  
the	  field	  of	  tissue	  engineering,	  it	  is	  increasingly	  being	  realized	  that	  the	  future	  of	  the	  
field	  will	  greatly	  benefit	  from	  this	  noninvasive	  approach	  to	  studying	  dynamic	  
changes	  that	  occur	  during	  neotissue	  development	  in	  vivo.	  	  The	  paucity	  of	  
noninvasive	  techniques	  currently	  available	  to	  monitor	  the	  fate	  of	  transplanted	  
tissue	  engineered	  constructs	  is	  commonly	  cited	  as	  one	  of	  the	  major	  challenges	  
facing	  the	  translation	  of	  regenerative	  medicine	  into	  the	  clinical	  realm	  (74).	  
The	  field	  of	  cellular	  MRI	  is	  a	  burgeoning	  field	  that	  allows	  noninvasive	  
monitoring	  of	  biological	  processes	  in	  vivo	  (68).	  In	  has	  been	  widely	  used	  for	  cell	  
tracking	  and	  enhanced	  visualization	  of	  in	  vivo	  processes,	  with	  related	  areas	  of	  
research	  also	  using	  MRI	  contrast	  agent	  cell	  labeling	  to	  guide	  cell	  delivery	  and	  to	  
enhance	  cellular	  therapeutic	  approaches	  with	  interventional	  MRI	  (44,88,89).	  	  A	  
noninvasive	  approach	  is	  instrumental	  for	  determining	  the	  trafficking	  and	  
biodistribution	  of	  cells	  in	  vivo	  after	  delivery,	  whether	  they	  are	  functioning	  or	  have	  
differentiated	  into	  the	  desired	  cell	  type,	  and	  whether	  the	  cells	  reach	  their	  target	  and	  
how	  long	  they	  reside	  there.	  All	  of	  the	  information	  gained	  from	  tracking	  can	  be	  used	  
to	  ensure	  the	  appropriate	  route	  of	  delivery,	  provide	  feedback	  into	  the	  preferred	  site	  
of	  engraftment	  and	  aid	  in	  determining	  the	  optimal	  dosing	  schedule	  and	  numbers	  of	  
cells	  to	  be	  used	  to	  achieve	  desired	  therapeutic	  outcome	  (90).	  	  
For	  cell	  tracking	  purposes,	  the	  most	  widely	  used	  applications	  consist	  of	  
cellular	  tracking	  of	  macrophages	  in	  CNS	  and	  atherosclerotic	  disease	  (58-­‐61)	  
providing	  evidence	  that	  it	  would	  be	  well	  suited	  for	  a	  similar	  purpose	  in	  vascular	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tissue	  engineering.	  However,	  to	  date,	  most	  applications	  of	  cellular	  MRI	  in	  the	  field	  of	  
vascular	  tissue	  engineering	  have	  been	  limited	  to	  mostly	  proof-­‐of-­‐principle	  studies	  
that	  show	  the	  promising	  feasibility	  of	  using	  these	  technologies	  in	  the	  future	  to	  study	  
TEVG	  development	  and	  in	  the	  clinical	  setting	  to	  monitor	  graft	  patency	  (79,42,75).	  To	  
our	  knowledge,	  no	  group	  has	  used	  cellular	  MRI	  technology	  to	  answer	  a	  question	  
about	  the	  mechanism	  of	  in	  vivo	  neovessel	  development	  in	  vascular	  tissue	  
engineering	  prior	  to	  this	  study.	  We	  are	  setting	  the	  stage	  for	  the	  future	  of	  
noninvasive	  monitoring	  studies	  to	  help	  delineate	  the	  exact	  mechanism	  of	  neovessel	  
development	  with	  the	  hopes	  of	  creating	  improved	  TEVGs	  for	  use	  in	  congenital	  heart	  
surgery.	  In	  addition,	  a	  noninvasive	  monitoring	  technique	  in	  the	  clinical	  setting	  
would	  allow	  physicians	  to	  monitor	  the	  development	  and	  function	  of	  TEVGs	  in	  
patients	  with	  the	  idea	  that	  visualization	  of	  aberrant	  development	  could	  potentially	  
lead	  to	  early	  therapeutic	  intervention.	  	  
	   This	  data	  is	  very	  promising	  for	  the	  use	  of	  cellular	  MRI	  in	  vascular	  tissue	  
engineering.	  However,	  there	  are	  still	  several	  limitations	  associated	  with	  the	  use	  of	  
USPIO	  particles	  for	  cell	  tracking	  and	  with	  the	  currently	  available	  MRI	  technology.	  	  
While	  the	  use	  of	  iron	  oxide	  based	  contrast	  agents	  is	  currently	  the	  predominantly	  
utilized	  nanoparticle	  contrast	  agent	  for	  cellular	  MRI	  there	  are	  still	  several	  
limitations	  surrounding	  their	  use.	  	  One	  major	  limitation	  is	  the	  fact	  that	  iron	  oxide	  is	  
a	  T2	  contrast	  agent	  that	  creates	  a	  negative	  contrast	  or	  hypointense	  (dark)	  signal.	  
This	  signal	  may	  be	  confounded	  with	  similar	  hypointense	  MR	  signals	  originating	  
from	  the	  vasculature,	  hemorrhages,	  or	  tumors	  (54).	  In	  addition,	  void	  detection	  is	  
dependent	  on	  image	  resolution	  which	  is	  limited	  by	  partial	  volume	  effects	  (90).	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These	  drawbacks	  are	  being	  overcome	  by	  the	  trend	  of	  producing	  agents	  with	  lower	  
thresholds	  of	  detectability,	  the	  installation	  of	  scanners	  with	  higher	  field	  strengths	  
(55),	  and	  a	  focus	  on	  imaging	  the	  off-­‐resonance	  effects	  (44).	  A	  final	  solution	  to	  this	  
problem	  involves	  the	  development	  of	  Gadolinium	  based	  nanoparticulate	  contrast	  
agents	  that	  have	  better	  cell	  toxicity	  profiles	  (91).	  	  
Another	  confounding	  factor	  is	  the	  possibility	  that	  the	  loss	  of	  MR	  signal	  could	  
be	  caused	  by	  dilution	  of	  the	  contrast	  agent	  through	  cell	  division	  or	  biodegradation	  
instead	  of	  dispersion	  of	  cells	  carrying	  the	  label	  (79).	  There	  has	  been	  some	  initial	  
work	  on	  overcoming	  this	  problem	  of	  signal	  dilution	  secondary	  to	  cell	  division	  by	  
utilizing	  MR	  reporter	  genes	  or	  contrast	  agents	  that	  are	  activated	  by	  conditional	  
upregulation	  of	  enzymes	  (92,93).	  However,	  many	  research	  groups	  have	  shown	  that	  
although	  the	  iron	  load	  is	  diluted	  with	  cell	  division,	  the	  signal	  is	  still	  strong	  enough	  to	  
be	  detected	  for	  at	  least	  seven	  days	  and	  even	  longer	  depending	  on	  the	  rate	  of	  cell	  
division	  and	  initial	  iron	  load	  (57,74,79).	  	  
	   In	  our	  work,	  it	  is	  possible	  that	  the	  increase	  in	  T2	  signal	  was	  caused	  by	  the	  
rapid	  exocytosis	  or	  metabolism	  of	  the	  iron	  oxide	  particles.	  However,	  this	  is	  unlikely	  
due	  to	  the	  time	  frame	  with	  which	  the	  signal	  increased	  and	  previously	  reported	  
evidence	  that	  macrophages	  are	  able	  to	  retain	  endocytosed	  iron	  oxide	  particles	  in	  
large	  enough	  quantities	  produce	  a	  drop	  in	  MR	  signal	  intensity	  for	  at	  least	  ten	  days	  
post-­‐labeling	  (80).	  Terrovitis	  et	  al.	  (75)	  demonstrated	  ferumoxide	  labeling	  that	  
remained	  effective	  on	  scans	  up	  to	  four	  weeks	  after	  the	  labeling	  procedure.	  	  
	   One	  major	  limitation	  with	  bringing	  this	  technology	  into	  the	  clinical	  realm	  is	  
the	  current	  lack	  of	  interest	  in	  MR-­‐compatible	  device	  development	  (44).	  MRI	  has	  not	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yet	  become	  a	  part	  of	  standard	  laboratory	  equipment.	  This	  is	  mostly	  due	  to	  the	  large	  
investment	  that	  goes	  into	  maintaining	  a	  superconducting	  MRI	  device	  as	  well	  as	  the	  
lack	  of	  development	  of	  specially	  designed	  coils	  and	  other	  equipment	  necessary	  to	  
image	  samples	  of	  multiple	  sizes	  and	  shapes	  (51).	  In	  addition,	  the	  most	  widely	  used	  
strategy	  for	  increasing	  the	  spatial	  resolution	  (a	  requirement	  for	  cell	  tracking	  
application)	  requires	  the	  use	  of	  high-­‐field	  MRI	  to	  increase	  the	  signal	  to	  noise	  ratio	  
(SNR)	  in	  a	  voxel	  by	  enhancing	  the	  magnetic	  field	  strength.	  However,	  high-­‐field	  MRI	  
is	  not	  currently	  available	  in	  the	  clinical	  setting	  and	  has	  several	  limitations	  such	  as	  
high	  cost,	  reduced	  bore	  size,	  and	  artifact	  susceptibility.	  Poirier-­‐Quinot	  et	  al.	  propose	  
an	  alternative	  approach	  using	  a	  high-­‐temperature	  superconducting	  (HTS)	  cryo-­‐
cooled	  detection	  coil	  to	  increase	  the	  SNR	  (74).	  Yet,	  this	  approach	  also	  has	  a	  major	  
limitation	  in	  that	  it	  only	  permits	  high-­‐resolution	  in	  a	  small	  volume	  limiting	  the	  
region	  of	  interest	  that	  can	  be	  visualized.	  	  
Another	  alternative	  approach	  was	  recently	  published	  by	  Nitzsche	  et	  al.,	  
demonstrating	  the	  feasibility	  of	  using	  benchtop-­‐MRI	  (BT-­‐MRI)	  as	  an	  affordable	  and	  
powerful	  analytic	  tool	  for	  monitoring	  tissue	  engineered	  constructs	  (51).	  The	  main	  
reason	  that	  BT-­‐MRI	  is	  more	  affordable	  is	  due	  to	  the	  low	  static	  magnetic	  field	  
strength	  of	  0.5T	  and	  the	  absence	  of	  a	  helium	  cooling	  system.	  Nitzsche	  et	  al.	  
demonstrated	  the	  ability	  of	  BT-­‐MRI	  to	  characterize	  tissue-­‐engineered	  scaffolds	  as	  
well	  as	  to	  track	  SPIO-­‐labeled	  cells	  seeded	  onto	  the	  scaffolds.	  They	  concluded	  that	  
this	  might	  open	  the	  door	  for	  BT-­‐MRI	  to	  become	  a	  more	  lab-­‐oriented	  and	  accessible	  
tool	  for	  monitoring	  tissue-­‐engineered	  constructs	  allowing	  for	  the	  advancement	  of	  
MRI	  as	  a	  tool	  for	  noninvasive	  monitoring	  in	  tissue	  engineering	  applications.	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   Although	  there	  are	  still	  significant	  limitations	  with	  this	  technology,	  more	  
groups	  are	  realizing	  the	  importance	  of	  using	  noninvasive	  techniques	  to	  study	  the	  
dynamic	  changes	  that	  occur	  as	  their	  tissue-­‐engineered	  constructs	  develop.	  
Noninvasive	  monitoring	  of	  tissue	  growth	  is	  required	  for	  the	  future	  of	  tissue	  
engineering	  and	  these	  techniques	  are	  becoming	  a	  focus	  in	  the	  field.	  In	  our	  research	  
group,	  we	  are	  already	  beginning	  to	  build	  on	  our	  current	  results	  by	  performing	  
additional	  cell	  tracking	  studies	  that	  will	  help	  refine	  our	  knowledge	  of	  how	  neotissue	  
develops	  in	  our	  model	  of	  TEVG	  development.	  We	  have	  been	  able	  to	  show	  the	  rapid	  
loss	  of	  seeded	  cells	  from	  the	  implanted	  TEVG	  and	  now	  we	  are	  working	  to	  show	  the	  
infiltration	  of	  cells	  into	  the	  TEVG	  from	  the	  host.	  From	  previous	  reports	  we	  know	  
that	  after	  the	  seeded	  cells	  are	  lost	  from	  the	  implanted	  TEVG,	  there	  is	  a	  rapid	  
infiltration	  of	  host	  macrophages	  that	  initiate	  an	  inflammatory	  process	  of	  vascular	  
remodeling	  (33).	  The	  next	  phase	  of	  this	  research	  will	  involve	  labeling	  host	  
macrophages	  with	  USPIO	  and	  tracking	  their	  infiltration	  into	  implanted	  TEVGs	  with	  
cellular	  MRI.	  To	  accomplish	  this	  we	  will	  try	  both	  ex	  vivo	  and	  in	  vivo	  macrophage	  cell	  
labeling.	  In	  the	  former	  method,	  macrophages	  will	  be	  incubated	  with	  USPIO	  particles	  
ex	  vivo	  and	  then	  injected	  into	  SCID/bg	  mice	  after	  they	  have	  had	  TEVGs	  implanted.	  In	  
the	  latter	  method,	  USPIO	  particles	  will	  be	  injected	  into	  SCID/bg	  mice	  to	  see	  if	  
adequate	  in	  vivo	  macrophage	  cell	  labeling	  can	  be	  achieved.	  In	  both	  cases,	  serial	  MR	  
imaging	  will	  be	  performed	  to	  follow	  the	  migration	  of	  USPIO-­‐labeled	  macrophages	  
into	  the	  TEVG	  from	  the	  host	  vasculature.	  	  
	   Once	  this	  technology	  becomes	  more	  widespread	  with	  the	  development	  of	  
more	  sensitive	  MR	  contrast	  agents	  and	  with	  increased	  access	  to	  more	  advanced	  MR	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technology	  it	  is	  easy	  to	  see	  how	  it	  will	  become	  an	  integral	  part	  of	  vascular	  tissue	  
engineering.	  The	  future	  of	  cellular	  MRI	  goes	  beyond	  noninvasive	  monitoring	  and	  can	  
extend	  into	  the	  realm	  of	  directed	  TEVG	  development	  by	  coupling	  MRI	  contrast	  
agents	  with	  drug	  delivery	  systems	  (54).	  	  In	  clinical	  applications,	  noninvasive	  
monitoring	  of	  macrophages	  can	  be	  used	  as	  an	  early	  method	  to	  identify	  patients	  at	  
risk	  for	  graft	  stenosis	  leading	  to	  early	  intervention.	  Cellular	  MRI	  is	  a	  powerful	  tool	  in	  
the	  field	  of	  vascular	  tissue	  engineering	  that	  is	  critical	  to	  delineating	  the	  specific	  
mechanism	  of	  neovessel	  development	  as	  TEVGs	  undergo	  dynamic	  changes	  in	  our	  
small	  animal	  model.	  Knowledge	  gained	  through	  this	  research	  will	  be	  instrumental	  in	  
creating	  improved	  TEVGs,	  for	  directing	  neovessel	  development,	  and	  for	  use	  in	  the	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